var title_f0_27_432="Pericardium anatomy PI";
var content_f0_27_432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The pericardium of the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pericardium is the sac that surrounds the heart. It normally functions to protect the heart and reduce friction between the heart and surrounding organs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_432=[""].join("\n");
var outline_f0_27_432=null;
var title_f0_27_433="Acetic acid mag Endosc2";
var content_f0_27_433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Magnification endoscopy in a patient with Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnification endoscopy following instillation of acetic acid in a patient suspected of having short-segment Barrett's esophagus (left panel). The magnified image (right panel) shows a villous pattern, typical for intestinal metaplasia, which was confirmed on biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_433=[""].join("\n");
var outline_f0_27_433=null;
var title_f0_27_434="Diagram of fetal membranes";
var content_f0_27_434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Amnion, chorion, fetal fibronectin (fFN), and decidua",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_434=[""].join("\n");
var outline_f0_27_434=null;
var title_f0_27_435="Primary syphilis chancre";
var content_f0_27_435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penile chancre of primary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_435=[""].join("\n");
var outline_f0_27_435=null;
var title_f0_27_436="Radical vulvectomy3";
var content_f0_27_436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Kelly forcep has been passed in the midline to split the crura of the clitoris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of C. William Helm, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_436=[""].join("\n");
var outline_f0_27_436=null;
var title_f0_27_437="Deceased and living donor renal allograft recovery";
var content_f0_27_437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Deceased and living donor renal allograft recovery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/437/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/437/contributors\">",
"     Ron Shapiro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/437/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/437/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/437/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/437/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/27/437/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until totally implantable bioartificial or laboratory-grown kidneys become available, transplant surgeons must retrieve kidneys from deceased or living donors. An enormous part of the success of renal transplantation is predicated on the technically perfect recovery of the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The technical aspects of deceased and living donor renal allograft recovery will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DECEASED DONOR KIDNEYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the time, a number of different organs will be recovered from a single deceased donor, potentially including the heart, lungs, liver, pancreas, kidneys, and intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The kidneys can be reliably predicted to be the last organs to be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deceased donor will have been given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    (to promote vasodilatation) prior to aortic cross clamping. Donor pretreatment with dopamine may decrease the requirement for dialysis after kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/6\">",
"     6",
"    </a>",
"    ]. In a randomized prospective study, for example, the administration of low dose dopamine (4",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min) for a median period of 344 minutes resulted in a decreased need for multiple dialyses post-transplant (25 versus 35 percent, 95% CI 0.35-0.83) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus with respect to donor management, a low-threshold should exist to initiate low-dose dopamine early in the donor transplant management.",
"   </p>",
"   <p>",
"    Via a cannula placed in the distal aorta, the kidneys are kept cold by an in-situ flush with an intracellular type of preservation solution. In the United States, the most popular is the University of Wisconsin (Viaspan&reg;) solution; however, there has been an increase over the past several years in the utilization of HTK solution as an alternative. There is some evidence that the HTK and University of Wisconsin solutions provide similar patient and allograft survival rates [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/7\">",
"     7",
"    </a>",
"    ]. The kidneys are usually not seen or mobilized prior to aortic cross clamping, as such manipulation can adversely affect the liver.",
"   </p>",
"   <p>",
"    Once the thoracic and upper abdominal organs have been removed, the right colon and distal small bowel are mobilized medially and superiorly, and the right kidney is exposed. The right kidney is then mobilized medially, with Gerota's fascia, from the retroperitoneum. The left colon is then mobilized medially and superiorly, and the lower splanchnic nerves are divided. The left kidney, again with Gerota's fascia, is mobilized medially.",
"   </p>",
"   <p>",
"    Next, the ureters are divided near their insertion into the bladder, and are mobilized, with generous amounts of periureteral tissue up to the level of the lower pole of the kidneys. The distal aorta is then divided below the cannula, and the inferior vena cava is divided just above the confluence of the common iliac veins. All four structures, ie, the two ureters, vena cava, and aorta, are held up together with clamps, and dissection is carried out superiorly, directly on the spine, to a point above the renal artery and vein orifices. The suprarenal aorta and vena cava are then transected, and any additional connective tissue divided. Both kidneys are then removed en bloc and placed in a basin of ice-cold solution.",
"   </p>",
"   <p>",
"    At this point, the kidneys can be separated (although very small pediatric kidneys [from donors less than one to two years of age] may be kept together and transplanted en bloc). The left renal vein is dissected free at its insertion into the inferior vena cava, and a cuff of vena cava containing the left renal vein orifice is excised, leaving the remainder of the vena cava with the right kidney. The left renal vein can then be dissected free beyond the aorta.",
"   </p>",
"   <p>",
"    The kidneys are then flipped over, and the posterior aorta is divided between the lumbar arteries. The renal artery orifices can now be identified. The kidneys are then flipped over again, and the anterior aorta is divided in half longitudinally. A small amount of remaining connective tissue will remain, which is easily divided.",
"   </p>",
"   <p>",
"    The kidneys are now completely separated. Most of Gerota's fascia is then removed from each kidney, to ensure proper cooling of the kidney. The anatomic structures are described, and the renal arteries are flushed with 250 mL of chilled UW or HTK solution prior to packaging the kidneys. It is important that excessive fat be removed prior to packaging so that the fat does not act as an insulator, preventing uniform and rapid cooling of the entire kidney.",
"   </p>",
"   <p>",
"    With pulsatile preservation, the separated or unseparated kidneys are placed in a special cassette and the aorta or renal arteries are connected to the pulsatile preservation tubing. In this setting, much of the back table dissection may need to be performed early. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14866?source=see_link\">",
"     \"Overview of the surgery of deceased donor renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of donor kidneys of questionable viability, wedge biopsies of the kidneys can be performed for histologic evaluation prior to packaging or placement on the pulsatile preservation apparatus.",
"   </p>",
"   <p>",
"    In one published study, machine or pulsatile perfusion, versus cold storage, appeared to reduce the incidence of delayed allograft function and improve allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/8\">",
"     8",
"    </a>",
"    ]. In this trial, one kidney from 366 consecutive deceased donors was randomly assigned to machine perfusion and the other kidney to cold storage [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/8\">",
"     8",
"    </a>",
"    ]. The outcomes of patients who received these 672 kidneys were subsequently evaluated at one year. Compared with cold storage, machine perfusion significantly reduced the incidence of delayed graft function from 26.5 to 20.8 percent (adjusted odds ratio 0.57, 95% CI 0.36-0.88) and improved allograft survival at one year (94 versus 90 percent).",
"   </p>",
"   <p>",
"    The effect of the preservation method on delayed graft function did not differ significantly between patients who received kidneys from donors after brain death and patients who received kidneys from donors after cardiocirculatory death. There was also a nonsignificant trend toward an increased incidence of primary nonfunction in the cold storage group (4.8 versus 2.1 percent, p = 0.08).",
"   </p>",
"   <p>",
"    In a follow-up report of this study, the three-year graft survival was better for machine perfused kidneys compared with cold storage (91 versus 87 percent, adjusted hazard ratio for graft failure (AHR) of 0.60) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/9\">",
"     9",
"    </a>",
"    ]. Subgroup analysis showed improved three-year survival associated with machine perfusion for expanded criteria kidneys (86 versus 76 percent, AHR of 0.38) and for kidneys donated after brain death (91 versus 86 percent, AHR 0.54), but not for kidneys donated after circulatory death. There was no difference between groups in patient survival.",
"   </p>",
"   <p>",
"    Although the magnitude of benefit was not large, there appears to be enough benefit associated with pulsatile preservation to justify its continued use in routine clinical practice.",
"   </p>",
"   <p>",
"    Machine perfusion adds significant expense to kidney retrieval, and further study is required to confirm these results before a firm recommendation regarding its use is made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LIVING DONOR KIDNEYS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Open technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few technical variations regarding the performance of an open donor nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. In most cases, the living donor is placed on",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    side, and the table is maximally flexed under the twelfth rib, to expose the space between the ribs and the iliac crest. The kidney bar may be raised underneath the twelfth rib, to improve the exposure. The incision may be rib&ndash;sparing, below the twelfth or eleventh rib, or may involve the removal of one or more ribs, to facilitate exposure of the kidney and the renal hilum.",
"   </p>",
"   <p>",
"    A flank incision is made, commonly from the lateral order of the left rectus, at the level of the umbilicus, to a point underneath the twelfth rib. The subcutaneous and fascial layers are incised to the level of the peritoneum, and the latter is mobilized medially and anteriorly to expose the ureter. The ureter is dissected free for a short distance, and the kidney is then dissected free from the Gerota's Fascia. The kidney will come down as it is dissected free. The ureter is then mobilized superiorly, and the renal vein and artery are dissected free. Periarterial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    is infiltrated to prevent arterial spasm, and the branches of the renal vein are divided between ligatures as needed to obtain adequate length. The ureter is then dissected free distally to the level of the bifurcation of the common iliac artery. Care is taken not to dissect too closely near the ureter, to minimize the risk of devascularizing it. The distal ureter is clamped and divided, ligated distally, and tagged at the proximal end with a small clamp. During the course of the dissection, small doses of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    (5 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    (12.5 grams) are administered, along with a sufficient volume of intravenous fluid, to ensure a brisk diuresis of the kidneys.",
"   </p>",
"   <p>",
"    When the recipient is ready, and the donor kidney has been completely mobilized, the proximal renal artery is clamped and divided; the distal renal vein is then clamped and divided, and the kidney is removed. The kidney is then flushed on the back table with a cold solution containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (a locally used example is Ringer's Lactate with 10,000 units of",
"    <span class=\"nowrap\">",
"     heparin/liter)",
"    </span>",
"    and taken to the adjacent operating room to be transplanted. In this manner, systemic heparinization of the donor is avoided (although some surgeons still anticoagulate the donor with heparin). After removal of the kidney, the donor artery and vein stumps are securely oversewn and ligated, hemostasis is achieved, and the wound is closed using standard techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laparoscopic-assisted technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic-assisted donor nephrectomy has become the preferred technique in some centers [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. The positioning is similar to that utilized for the open technique, but instead of the open retroperitoneal exposure of the kidney, an intraperitoneal approach is employed. With the laparoscopic-assisted technique, three to five trocars are inserted to establish ports, ranging in size from 5 to 12 millimeters. One port is used for carbon dioxide insufflation, one for a video camera, and the others for the laparoscopic surgical knife and clamps (the carbon dioxide can usually be attached to a trocar being used for another purpose). After insufflation with carbon dioxide to a pressure of approximately 10 to 15 mmHg, the left colon is mobilized medially to expose the kidney, and the splenorenal ligament is divided. Laparoscopic dissection is then used to mobilize the kidney and expose the artery, vein, and ureter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/56/16262?source=see_link\">",
"     \"Benefits and complications of laparoscopic donor nephrectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with non-laparoscopic techniques, there are similar issues with laparoscopy regarding small doses of intravenous diuretics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , and periarterial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    . Intravenous volume requirements may be greater than those utilized in open cases, to counteract the effect of the intraperitoneal gas on renal blood flow. As an example, a donor will commonly receive 6 to 10 liters of isotonic fluids to maintain urine output above 50 cc per hour. When the kidney is ready to be removed, a small (5 to 7 cm) incision is made to allow for basketing and removal of the kidney, after stapling the artery and vein. The use of Weck Hem-o-Lock surgical clamps to ligate the renal artery has been associated with life-threatening hemorrhage among patients undergoing laparoscopic kidney donation, and they are contraindicated for this use. The United States Food and Drug Administration (FDA) has issued an alert that these clamps NOT be used for ligation of the renal artery during laparoscopic living-donor nephrectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/437/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individual centers differ with regard to the location of the incision, the administration of systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and the use of a hand-assisted technique to help with mobilization and removal of the kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30813733\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The success of renal transplantation depends in part on the technically perfect recovery of the kidney. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A kidney is recovered from a deceased donor after the donor has been given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and often",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       phentolamine",
"      </a>",
"      to promote vasodilatation. Donor pretreatment with dopamine may decrease the requirement for dialysis after kidney transplantation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Deceased donor kidneys'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to removal from a deceased donor, the kidneys are kept cold by an in-situ flush with an intracellular preservation solution that is either the University of Wisconsin (Viaspan&reg;) solution or HTK solution. Kidneys are removed en bloc and placed in ice-cold solution prior to being separated. Gerota's fascia and excessive fat are removed to ensure proper cooling of the kidney and the renal arteries are flushed with chilled UW or HTK solution prior to packaging. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When donor kidneys are of questionable viability wedge biopsies may be performed for histologic evaluation prior to packaging or placement on the pulsatile preservation apparatus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Donor nephrectomy from a living donor may be done via an open or laparoscopic-assisted technique. Whereas the open technique utilizes retroperitoneal exposure of the kidney, the laparoscopic technique employs an intraperitoneal approach. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Living donor kidneys'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In both open and laparoscopic techniques for kidney dissection from a living donor, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      (5 mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      (12.5 grams) are given with intravenous fluid to ensure a brisk diuresis of the kidneys. Intravenous volume requirements may be greater when a laparoscopic technique is used. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Living donor kidneys'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individual centers differ with regard to the location of the incision, the administration of systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , and the use of a hand-assisted technique to help with mobilization and removal of the kidney. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Living donor kidneys'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/1\">",
"      Asolati, M, Matas, AJ. Risks versus benefits of living kidney donation. Curr Opin Organ Transplant 2003; 8:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/2\">",
"      Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med 2004; 351:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/3\">",
"      Humar A, Matas AJ. Surgical complications after kidney transplantation. Semin Dial 2005; 18:505.",
"     </a>",
"    </li>",
"    <li>",
"     Shapiro, R, Simmons, RL. Renal Transplantation. In: Atlas of Organ Transplantation, Starzl, TE, Shapiro, R, Simmons, RL (Eds), Gower Medical Publishing, New York, 1992.",
"    </li>",
"    <li>",
"     Scantlebury, V. Cadaveric and Living Donation. In: Renal Transplantation, Shapiro, R, Simmons, R, Starzl, TE (Eds), Appleton and Lange, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/6\">",
"      Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009; 302:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/7\">",
"      Lynch RJ, Kubus J, Chenault RH, et al. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin preservation in renal transplantation. Am J Transplant 2008; 8:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/8\">",
"      Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/9\">",
"      Moers C, Pirenne J, Paul A, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2012; 366:770.",
"     </a>",
"    </li>",
"    <li>",
"     Yanaga, K, Podesta, LG, Broznick, B, et al. Multiple Organ Recovery for Transplantation. In: Atlas of Organ Transplantation, Starzl, TE, Shapiro, R, Simmons, RL (Eds), Gower Medical Publishing, New York, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/11\">",
"      Ratner LE, Kavoussi LR, Sroka M, et al. Laparoscopic assisted live donor nephrectomy--a comparison with the open approach. Transplantation 1997; 63:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/12\">",
"      Flowers JL, Jacobs S, Cho E, et al. Comparison of open and laparoscopic live donor nephrectomy. Ann Surg 1997; 226:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/13\">",
"      Philosophe B, Kuo PC, Schweitzer EJ, et al. Laparoscopic versus open donor nephrectomy: comparing ureteral complications in the recipients and improving the laparoscopic technique. Transplantation 1999; 68:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/14\">",
"      Chan DY, Fabrizio MD, Ratner LE, Kavoussi LR. Complications of laparoscopic live donor nephrectomy: the first 175 cases. Transplant Proc 2000; 32:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/15\">",
"      Ratner LE, Buell JF, Kuo PC. Laparoscopic donor nephrectomy: pro. Transplantation 2000; 70:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/437/abstract/16\">",
"      Buell JF, Abreu SC, Hanaway MJ, et al. Right donor nephrectomy: a comparison of hand-assisted transperitoneal and retroperitoneal laparoscopic approaches. Transplantation 2004; 77:521.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm253237.htm.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7316 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_437=[""].join("\n");
var outline_f0_27_437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30813733\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DECEASED DONOR KIDNEYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LIVING DONOR KIDNEYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Open technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laparoscopic-assisted technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30813733\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/56/16262?source=related_link\">",
"      Benefits and complications of laparoscopic donor nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14866?source=related_link\">",
"      Overview of the surgery of deceased donor renal transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_27_438="Reconstruction with free TRAM flap PI";
var content_f0_27_438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Reconstruction with free TRAM flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 698px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Women who have reconstruction with a free TRAM have a flap of tissue cut out of their belly. The flap is made up of skin, fat, and a chunk of muscle. In this surgery, the flap is completely detached from the belly and then attached to the chest. Because the flap is completely detached, surgeons have to reconnect blood vessels that were cut. Unlike the pedicled TRAM surgery, this surgery does not involve creating a tunnel under the skin to put the flap in place. Later, surgeons can also reconstruct a nipple. TRAM stands for \"transverse rectus abdominus myocutaneous.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_438=[""].join("\n");
var outline_f0_27_438=null;
var title_f0_27_439="Nijmegen breakage syndrome";
var content_f0_27_439=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nijmegen breakage syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/439/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/439/contributors\">",
"     Andrew Gennery, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/439/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/439/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/439/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/439/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/27/439/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of human genetic disorders cause chromosomal breakage, which is characterized by genome instability that occurs in the basal state (spontaneously) or in response to DNA-damaging agents (",
"    <a class=\"graphic graphic_table graphicRef82574 \" href=\"UTD.htm?16/58/17324\">",
"     table 1",
"    </a>",
"    ). These disorders cause defects in the recognition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repair of damage to DNA inflicted by different agents. In most cases, the genome instability is associated with immunodeficiency, a predisposition to develop cancer, and premature aging [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss Nijmegen breakage syndrome (NBS, MIM 251260), which is a chromosomal breakage syndrome associated with immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Discussions relating to similar disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=see_link\">",
"     \"Bloom syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nijmegen breakage syndrome (NBS) is a rare disorder. The exact incidence is unknown. Most NBS patients have an ethnic origin from Eastern Europe, notably Poland and Czechoslovakia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. One study analyzed newborn screening cards for the most common NBS1 mutation (657del5) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence of this mutation ranged from",
"    <span class=\"nowrap\">",
"     1/154",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/190",
"    </span>",
"    in three Slavic populations, compared with",
"    <span class=\"nowrap\">",
"     1/866",
"    </span>",
"    in a German population reported in a separate study [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence of NBS was estimated to be",
"    <span class=\"nowrap\">",
"     1/95,000",
"    </span>",
"    live births in Czechoslovakia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nijmegen breakage syndrome is an autosomal recessive chromosomal instability disorder that is caused by mutations in the NBN gene on 8q21 that encodes the protein nibrin (MIM 602667) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/7\">",
"     7",
"    </a>",
"    ]. The most common mutation in patients of Eastern European descent is hypomorphic, leading to a partially functional protein [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/8\">",
"     8",
"    </a>",
"    ]. Other mutations are more common in different populations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nibrin forms a complex with MRE11 (the protein mutated in ataxia-telangiectasia-like disorder) and RAD50, and then rapidly localizes to the site of DNA double strand breaks. DNA breaks are not efficiently repaired in the absence of nibrin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. This protein complex is also involved in meiotic recombination and telomere maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In addition, nibrin plays a role in the initiation of base excision repair after oxidative or alkylating stress [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nijmegen breakage syndrome (NBS) is characterized by progressive severe microcephaly and a \"bird-like\" face, intrauterine growth retardation and short stature, immunodeficiency with recurrent sinopulmonary infections, a predisposition to malignancy, and primary ovarian insufficiency (premature ovarian failure) in females [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/2,3,16\">",
"     2,3,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a distinct pattern of malformations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virtually all patients have severe microcephaly, well below the third percentile and 10 to 12 cm in diameter less than mean for age [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/16\">",
"       16",
"      </a>",
"      ]. Microcephaly is present at birth in 75 percent of cases and develops in the rest of patients during early infancy. The microcephaly is progressive and is associated with a decline in cognitive skills that results in mild to moderate mental retardation by 7 to 10 years of age. Autopsy studies and cranial magnetic resonance imaging (MRI) have attributed this problem to stunted brain growth with particularly severe effects on the frontal lobes and corpus callosum [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. The cerebellum appears to be normal.",
"     </li>",
"     <li>",
"      Patients with NBS also have abnormal facies with a sloping forehead, receding mandible, prominent mid-face, long nose, and upward slant of the palpebral fissures. These facial features become more prominent as the microcephaly progresses and are recognizable beginning around three years of age.",
"     </li>",
"     <li>",
"      Other malformations occur in as many as 50 percent of patients. These include clinodactyly and syndactyly,",
"      <span class=\"nowrap\">",
"       atresia/stenosis",
"      </span>",
"      along the gastrointestinal tract, choanal atresia, cleft lip and palate, hydronephrosis, and hip dysplasia. Hypergonadotropic hypogonadism is common in affected males and leads to infertility [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/19\">",
"       19",
"      </a>",
"      ]. Ovarian dysgenesis and premature ovarian failure occurs in affected females [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients may be small for gestational age at birth and growth retardation typically occurs in the first two years of life. After that, growth velocity usually returns to normal. However, height is usually below the third percentile because of the initial growth delay.",
"   </p>",
"   <p>",
"    Many patients develop caf&eacute;-au-lait spots and depigmented skin lesions. Porokeratosis, a hyperkeratotic disorder, and cutaneous noncaseating granulomas have been reported in patients with NBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cancer is the leading cause of death for patients with NBS, with 40 percent of patients developing a malignancy before 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/23\">",
"     23",
"    </a>",
"    ]. The majority of cancers are lymphomas, but there have been case reports of glioma, rhabdomyosarcoma, and medulloblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. An increased susceptibility to malignancy has been reported in heterozygotes, although they appear to be normal in other respects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients suffer from recurrent upper and lower respiratory tract infections (pneumonia, bronchitis, sinusitis, otitis media, and mastoiditis). Chronic lung disease with bronchiectasis is the second leading cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/23\">",
"     23",
"    </a>",
"    ]. Oral candidiasis and gingival hyperplasia have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/30\">",
"     30",
"    </a>",
"    ]. There are no published reports of opportunistic infections, but there is evidence of more generalized immune dysfunction with patients exhibiting autoimmune (immune thrombocytopenia and hemolytic anemia) and chronic inflammatory (childhood sarcoidosis) disorders at much higher than expected frequencies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/23,31\">",
"     23,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary ovarian insufficiency is common in females with NBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunodeficiency is common in NBS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/23,32\">",
"     23,32",
"    </a>",
"    ]. One-third of patients are agammaglobulinemic. As many as 80 percent of the others have absent or low levels of one or more immunoglobulin classes or IgG subclasses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/23,33\">",
"     23,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients are lymphopenic, with relatively similar diminution of CD4+ and CD8+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/23\">",
"     23",
"    </a>",
"    ] as well as decreased CD19+ cells due to a quantitative VDJ recombination deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition most patients have reduced in vitro proliferative responses to mitogens [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/23\">",
"     23",
"    </a>",
"    ]. At autopsy, the thymus is small and devoid of Hassall's corpuscles, suggesting dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/17\">",
"     17",
"    </a>",
"    ]. Lymph nodes have normal architecture, but lymphoid follicles are small and germinal centers are reduced in number.",
"   </p>",
"   <p>",
"    The characteristic laboratory abnormality in NBS is chromosome instability. Cultured T cells show an extremely low mitotic index making cytogenetic analysis difficult, but structural chromosomal aberrations are present in 10 to 35 percent of metaphases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/35\">",
"     35",
"    </a>",
"    ]. Most of the rearrangements occur in chromosomes 7 and 14 at the locations of immunoglobulin and T cell receptor genes, and may be present in as many as a third of tested lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypersensitivity to x-rays is documented in both lymphocytes and fibroblasts from patients with NBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/36\">",
"     36",
"    </a>",
"    ]. The extent of sensitivity is comparable to that observed in patients with ataxia-telangiectasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most prominent feature of NBS is severe microcephaly. Although the differential diagnosis of microcephaly is extensive, the relatively mild retardation and characteristic facies should point to the diagnosis of NBS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and evaluation of microcephaly in infants and children\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A range of laboratory tests is required for confirmation of the diagnosis. Demonstration of chromosomal rearrangements typically involving chromosomes 7 and 14, as well as chromosomal hypersensitivity to x-irradiation, suggests NBS or an associated disorder such as DNA ligase IV deficiency or",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF",
"    </span>",
"    deficiency. Immunoblotting and molecular genetic testing are required to confirm the diagnosis. The 657 del 5 mutation of the NBS1 gene on 8q21 is present in approximately 85 percent of cases in the United States, simplifying the task of genetic confirmation in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link&amp;anchor=H7#H7\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\", section on 'XRCC4 and DNA ligase IV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link&amp;anchor=H8#H8\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\", section on 'Cernunnos/XLF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prenatal diagnosis and carrier detection using molecular genetic testing is available for those with affected family members whose mutations are known.",
"   </p>",
"   <p>",
"    A list of laboratories offering clinical testing for NBS is available at",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/8497?db=genetests\">",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/8497?db=genetests",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disease shares the laboratory feature of x-ray sensitivity observed with ataxia-telangiectasia and ataxia-telangiectasia-like disease. However, NBS can be distinguished from these disorders in that there is no neurodegeneration, but rather microcephaly with mild to moderate mental retardation. In addition, unlike these two disorders, NBS patients do not have telangiectasia, and serum alpha-fetoprotein levels are normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Development delay, microcephaly, cancer predisposition, and immune abnormalities are also observed in Fanconi anemia. In two patients with suspected Fanconi anemia, the correct diagnosis of NBS was only discovered after chromosomal gene arrangement studies and sequence of the NBS gene [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deficiency of RAD50, which is part of the",
"    <span class=\"nowrap\">",
"     MRE11/RAD50/NBS",
"    </span>",
"    (MRN) complex (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above), presents with clinical features similar to NBS (eg, microcephaly, \"bird-like\" face, short stature, and mental retardation) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the first patient reported with RAD50 deficiency (also called Nijmegen breakage syndrome-like disorder, NBSLD, MIM 613078) had normal immunoglobulin levels, did not have a history of serious infections, and had not developed malignancy by age 23 years despite demonstration of chromosomal instability and radiosensitivity.",
"   </p>",
"   <p>",
"    Other syndromes sharing some clinical features with NBS that are associated with chromosomal instability and increased susceptibility to malignancy include DNA ligase I deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/39\">",
"     39",
"    </a>",
"    ], DNA ligase IV deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/40\">",
"     40",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF",
"    </span>",
"    deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/41\">",
"     41",
"    </a>",
"    ], Bloom syndrome, and Seckel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link&amp;anchor=H7#H7\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\", section on 'XRCC4 and DNA ligase IV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link&amp;anchor=H8#H8\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\", section on 'Cernunnos/XLF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=see_link\">",
"     \"Bloom syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for NBS.",
"   </p>",
"   <p>",
"    Sinopulmonary infections are most common, and may lead to bronchiectasis. Subjects should be evaluated for immunodeficiency and treated as appropriate with antibiotic prophylaxis, and in severe antibody deficiency, immune globulin replacement. Live vaccines should be avoided. Several patients, who either had severe immunodeficiency or resistant or secondary malignancy, have successfully undergone hematopoietic cell transplantation with reduced-intensity conditioning regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with NBS have a high risk of developing malignancy, predominantly lymphomas, with over 40 percent developing a malignancy by the age of 20 years. Parents and caregivers should be counseled about the presenting signs of lymphoma and other malignancies. Preliminary data suggest that monitoring for appearance of certain biomarkers that can precede malignancy (eg, monoclonal proteins,",
"    <span class=\"nowrap\">",
"     immunoglobulin/T",
"    </span>",
"    cell receptor gene rearrangements, and viral infections including Epstein Barr virus and hepatitis) may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with NBS have increased sensitivity to both radiation therapy and chemotherapy, which complicates treatment of malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Radiotherapy should be avoided, but if necessary, significantly decreased doses should be used. Several patients with lymphoma have been treated successfully with decreased doses of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Females with NBS should be monitored for primary ovarian insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/439/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life expectancy is reduced because of the tendency for NBS patients to develop malignancies at a young age. In some patients, immunodeficiency predisposes to the development of severe, sometimes fatal, infections. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nijmegen breakage syndrome is an autosomal recessive disorder characterized by chromosomal instability and radiosensitivity, immunodeficiency, short stature, microcephaly and a \"bird-like\" face, and a predisposition to malignancy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nijmegen breakage syndrome is caused by mutations in the NBN gene, which encodes for the protein nibrin that is involved in double strand DNA break repair, meiotic recombination, and telomere maintenance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic clinical features of Nijmegen breakage syndrome include severe microcephaly and a \"bird-like\" face, short stature, immunodeficiency with recurrent sinopulmonary infections, and a predisposition to malignancy. Carriers also have an increased risk of malignancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic laboratory abnormality in Nijmegen breakage syndrome is chromosome instability. Most patients are lymphopenic and about one-third have agammaglobulinemia. Alpha-fetoprotein levels are normal. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based upon the presence of characteristic clinical manifestation and confirmed by the demonstration of chromosomal rearrangements typically involving chromosomes 7 and 14, as well as chromosomal hypersensitivity to x-irradiation. The diagnosis can also be confirmed by identification of mutations in the NBN gene. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes ataxia-telangiectasia, Fanconi anemia, RAD50 deficiency, DNA ligase I and IV defects,",
"      <span class=\"nowrap\">",
"       Cernunnos/XLF",
"      </span>",
"      deficiency, Bloom syndrome and Seckel syndrome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific treatment for NBS. Subjects should be evaluated for immunodeficiency and treated as appropriate. Parents and caregivers should be counseled about the presenting signs of lymphoma and other malignancies. Radiation therapy should be avoided if possible. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/1\">",
"      Kamenisch Y, Berneburg M. Progeroid syndromes and UV-induced oxidative DNA damage. J Investig Dermatol Symp Proc 2009; 14:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/2\">",
"      Chrzanowska KH, Gregorek H, Dembowska-Bagiska B, et al. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 2012; 7:13.",
"     </a>",
"    </li>",
"    <li>",
"     Gene Reviews. file://www.ncbi.nlm.nih.gov/books/NBK1176/ (Accessed on March 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/4\">",
"      Weemaes CM, Hustinx TW, Scheres JM, et al. A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta Paediatr Scand 1981; 70:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/5\">",
"      Varon R, Seemanova E, Chrzanowska K, et al. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 2000; 8:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/6\">",
"      Carlomagno F, Chang-Claude J, Dunning AM, Ponder BA. Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer. Genes Chromosomes Cancer 1999; 25:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/7\">",
"      Antoccia A, Kobayashi J, Tauchi H, et al. Nijmegen breakage syndrome and functions of the responsible protein, NBS1. Genome Dyn 2006; 1:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/8\">",
"      Lins S, Kim R, Kr&uuml;ger L, et al. Clinical variability and expression of the NBN c.657del5 allele in Nijmegen Breakage Syndrome. Gene 2009; 447:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/9\">",
"      Carney JP, Maser RS, Olivares H, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998; 93:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/10\">",
"      Yuan J, Chen J. MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX. J Biol Chem 2010; 285:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/11\">",
"      Williams RS, Dodson GE, Limbo O, et al. Nbs1 flexibly tethers Ctp1 and Mre11-Rad50 to coordinate DNA double-strand break processing and repair. Cell 2009; 139:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/12\">",
"      Brugmans L, Verkaik NS, Kunen M, et al. NBS1 cooperates with homologous recombination to counteract chromosome breakage during replication. DNA Repair (Amst) 2009; 8:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/13\">",
"      Attwooll CL, Akpinar M, Petrini JH. The mre11 complex and the response to dysfunctional telomeres. Mol Cell Biol 2009; 29:5540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/14\">",
"      Deng Y, Guo X, Ferguson DO, Chang S. Multiple roles for MRE11 at uncapped telomeres. Nature 2009; 460:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/15\">",
"      Sagan D, M&uuml;ller R, Kr&ouml;ger C, et al. The DNA repair protein NBS1 influences the base excision repair pathway. Carcinogenesis 2009; 30:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/16\">",
"      Digweed M, Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 2004; 3:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/17\">",
"      Van de Kaa CA, Weemaes CM, Wesseling P, et al. Postmortem findings in the Nijmegen breakage syndrome. Pediatr Pathol 1994; 14:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/18\">",
"      Bekiesiska-Figatowska M, Chrzanowska KH, Sikorska J, et al. Cranial MRI in the Nijmegen breakage syndrome. Neuroradiology 2000; 42:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/19\">",
"      Warcoin M, Lespinasse J, Despouy G, et al. Fertility defects revealing germline biallelic nonsense NBN mutations. Hum Mutat 2009; 30:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/20\">",
"      Chrzanowska KH, Szarras-Czapnik M, Gajdulewicz M, et al. High prevalence of primary ovarian insufficiency in girls and young women with Nijmegen breakage syndrome: evidence from a longitudinal study. J Clin Endocrinol Metab 2010; 95:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/21\">",
"      Wolf EK, Shwayder TA. Nijmegen breakage syndrome associated with porokeratosis. Pediatr Dermatol 2009; 26:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/22\">",
"      Yoo J, Wolgamot G, Torgerson TR, Sidbury R. Cutaneous noncaseating granulomas associated with Nijmegen breakage syndrome. Arch Dermatol 2008; 144:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/23\">",
"      Nijmegen breakage syndrome. The International Nijmegen Breakage Syndrome Study Group. Arch Dis Child 2000; 82:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/24\">",
"      Gadkowska-Dura M, Dzierzanowska-Fangrat K, Dura WT, et al. Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation. J Pathol 2008; 216:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/25\">",
"      Ciara E, Piekutowska-Abramczuk D, Popowska E, et al. Heterozygous germ-line mutations in the NBN gene predispose to medulloblastoma in pediatric patients. Acta Neuropathol 2010; 119:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/26\">",
"      Huang J, Grotzer MA, Watanabe T, et al. Mutations in the Nijmegen breakage syndrome gene in medulloblastomas. Clin Cancer Res 2008; 14:4053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/27\">",
"      Seemanov&aacute; E. An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. Mutat Res 1990; 238:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/28\">",
"      Seemanov&aacute; E, Jarolim P, Seeman P, et al. Cancer risk of heterozygotes with the NBN founder mutation. J Natl Cancer Inst 2007; 99:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/29\">",
"      di Masi A, Antoccia A. NBS1 Heterozygosity and Cancer Risk. Curr Genomics 2008; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/30\">",
"      Gregorek H, Olczak-Kowalczyk D, Dembowska-Bagiska B, et al. Oral findings in patients with Nijmegen breakage syndrome: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108:e39.",
"     </a>",
"    </li>",
"    <li>",
"     Wegner RF, German JJ, Chrzanpwska KH, et al. Chromosomal instability syndromes other than ataxia-telangiectasia. In: Primary immunodeficiency syndromes: A molecular and genetic approach, Ochs HD, Smith CIE, Puck JM (Eds), Oxford University Press, Oxford 2007. p.432.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/32\">",
"      Chrzanowska KH, Kleijer WJ, Krajewska-Walasek M, et al. Eleven Polish patients with microcephaly, immunodeficiency, and chromosomal instability: the Nijmegen breakage syndrome. Am J Med Genet 1995; 57:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/33\">",
"      Gregorek H, Chrzanowska KH, Michakiewicz J, et al. Heterogeneity of humoral immune abnormalities in children with Nijmegen breakage syndrome: an 8-year follow-up study in a single centre. Clin Exp Immunol 2002; 130:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/34\">",
"      van der Burg M, Pac M, Berkowska MA, et al. Loss of juxtaposition of RAG-induced immunoglobulin DNA ends is implicated in the precursor B-cell differentiation defect in NBS patients. Blood 2010; 115:4770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/35\">",
"      Taalman RD, Hustinx TW, Weemaes CM, et al. Further delineation of the Nijmegen breakage syndrome. Am J Med Genet 1989; 32:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/36\">",
"      Taalman RD, Jaspers NG, Scheres JM, et al. Hypersensitivity to ionizing radiation, in vitro, in a new chromosomal breakage disorder, the Nijmegen Breakage Syndrome. Mutat Res 1983; 112:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/37\">",
"      Gennery AR, Slatter MA, Bhattacharya A, et al. The clinical and biological overlap between Nijmegen Breakage Syndrome and Fanconi anemia. Clin Immunol 2004; 113:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/38\">",
"      Waltes R, Kalb R, Gatei M, et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet 2009; 84:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/39\">",
"      Webster AD, Barnes DE, Arlett CF, et al. Growth retardation and immunodeficiency in a patient with mutations in the DNA ligase I gene. Lancet 1992; 339:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/40\">",
"      Chistiakov DA, Voronova NV, Chistiakov AP. Ligase IV syndrome. Eur J Med Genet 2009; 52:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/41\">",
"      Buck D, Malivert L, de Chasseval R, et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 2006; 124:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/42\">",
"      Griffith E, Walker S, Martin CA, et al. Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling. Nat Genet 2008; 40:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/43\">",
"      Albert MH, Gennery AR, Greil J, et al. Successful SCT for Nijmegen breakage syndrome. Bone Marrow Transplant 2010; 45:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/44\">",
"      Gregorek H, Chrzanowska KH, Dzierzanowska-Fangrat K, et al. Nijmegen breakage syndrome: Long-term monitoring of viral and immunological biomarkers in peripheral blood before development of malignancy. Clin Immunol 2010; 135:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/45\">",
"      Chistiakov DA, Voronova NV, Chistiakov PA. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol 2008; 47:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/46\">",
"      Pollard JM, Gatti RA. Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys 2009; 74:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/47\">",
"      Jovanovic A, Minic P, Scekic-Guc M, et al. Successful treatment of hodgkin lymphoma in nijmegen breakage syndrome. J Pediatr Hematol Oncol 2009; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/48\">",
"      Dembowska-Baginska B, Perek D, Brozyna A, et al. Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). Pediatr Blood Cancer 2009; 52:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/439/abstract/49\">",
"      Dumic M, Radman I, Krnic N, et al. Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome. Clin Lymphoma Myeloma 2007; 7:590.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3957 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_439=[""].join("\n");
var outline_f0_27_439=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3957\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3957|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/58/17324\" title=\"table 1\">",
"      Characteristics of chromosomal breakage syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=related_link\">",
"      Bloom syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=related_link\">",
"      Etiology and evaluation of microcephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_27_440="Developmental defects of the teeth";
var content_f0_27_440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Developmental defects of the teeth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/440/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/440/contributors\">",
"     J Tim Wright, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/440/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/440/contributors\">",
"     Ann Griffen, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/440/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/440/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/27/440/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The close relationship among oral, systemic, and psychologic health requires that oral health be evaluated thoroughly as part of health maintenance supervision. An understanding of the normal sequence and patterns of tooth eruption is the foundation for identifying and treating children with abnormal dental development and optimizing their oral health. Distinguishing normal from pathological dental development requires careful evaluation of the patient, including medical, dental, and family history; clinical examination; radiographic evaluation; and possibly special laboratory tests.",
"   </p>",
"   <p>",
"    Problems in dental development and syndromes associated with abnormal dental development are reviewed here. The normal anatomy and development of human dentition are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39590?source=see_link\">",
"     \"Anatomy and development of the teeth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ERUPTION PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems in tooth eruption include natal and neonatal teeth, premature eruption, and failed tooth eruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Natal and neonatal teeth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teeth that are present in the oral cavity at the time of birth are natal teeth; those that erupt during the neonatal period are neonatal teeth. The majority of natal teeth are the primary mandibular incisors and are not extra or supernumerary teeth (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60962 \" href=\"UTD.htm?26/52/27456\">",
"     image 1",
"    </a>",
"    ). Natal teeth may be associated with a variety of syndromes including chondroectodermal dysplasia (Ellis-van Creveld syndrome), pachyonychia congenita, Sotos syndrome, and Hallerman-Streiff syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of natal teeth may involve observation, smoothing of the incisal edge (to prevent potential discomfort during breastfeeding and ulceration in the floor of the mouth), or extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/2\">",
"     2",
"    </a>",
"    ]. Extraction of natal teeth should be considered only if they cause feeding difficulties for the infant or mother. Excessive natal tooth mobility has been considered to be a risk for aspiration. However, aspiration rarely, if ever, occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abnormal eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed and accelerated eruption of teeth are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39590?source=see_link&amp;anchor=H9#H9\">",
"     \"Anatomy and development of the teeth\", section on 'Tooth eruption'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Failed teeth eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete failure of eruption of the primary teeth is rare with the exception of congenitally missing teeth. On the other hand, eruption failure of a single permanent tooth in an otherwise healthy child is more common and has a number of causes. Mutations in the",
"    <em>",
"     PTHR1",
"    </em>",
"    gene are associated with primary failure of tooth eruption and can affect one or multiple permanent teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Congenitally missing teeth'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Inadequate space",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of permanent tooth eruption failure is lack of space for eruption. Space deficiency in the dental arch frequently causes eruption failure (impaction) of the third molars, the maxillary canines, and the mandibular second premolars [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/4\">",
"     4",
"    </a>",
"    ]. Inadequate eruption space also can lead eruption out of the normal position or ectopic eruption.",
"   </p>",
"   <p>",
"    Inadequate space for eruption is treated with selective extraction of permanent teeth or orthodontic therapy, depending upon the severity and location of the space deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma to the anterior primary teeth can affect the development of the underlying permanent teeth and result in eruption failure of the permanent incisors. The development and eruption of permanent teeth should be monitored closely in children who have a history of trauma to the anterior primary teeth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link\">",
"     \"Evaluation and management of dental injuries in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ankylosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankylosis, or fusion of the developing teeth to the underlying bone, can arrest the normal process of tooth eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/5\">",
"     5",
"    </a>",
"    ]. In a child who is still growing, the ankylosed tooth will be overgrown by the surrounding teeth that continue to erupt. Ankylosis should be suspected if a tooth fails to contact the teeth of the opposing arch when the teeth are brought into occlusion. Ankylosis most often involves the first primary molars (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57748 \" href=\"UTD.htm?5/17/5392\">",
"     image 1",
"    </a>",
"    ) and is relatively common in the primary dentition [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/5\">",
"     5",
"    </a>",
"    ]. Ankylosed primary teeth typically exfoliate normally without treatment if they have a permanent successor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/6\">",
"     6",
"    </a>",
"    ]; however, treatment for ankylosis may be necessary depending upon the age of onset and severity of the problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cleidocranial dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cleidocranial dysplasia is an autosomal dominant condition characterized by hypoplasia or aplasia of the clavicles, defective bone formation, short stature, supernumerary teeth, defective cementum formation, and abnormal permanent tooth eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The failure of tooth eruption is thought to be caused by impedance of the migration of the permanent teeth toward the oral cavity by defects in the osteoclastic and resorptive activity of the alveolar bone. Cleidocranial dysplasia is caused by a mutation in the runt-related transcription factor 2 gene (",
"    <em>",
"     RUNX2",
"    </em>",
"    ), a member of the RUNX family of transcription factors, located on chromosome 6p21. The",
"    <em>",
"     RUNX2",
"    </em>",
"    gene encodes core-binding factor alpha 1 (CFBA1) and is responsible for the initial differentiation of osteoblasts to form skeletal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the oral manifestations of cleidocranial dysplasia involves extracting the supernumerary teeth and assisting the eruption of the permanent teeth through surgery or orthodontia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885483159\">",
"    <span class=\"h3\">",
"     Primary failure of eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary failure of eruption is a failure of tooth eruption that is not caused by mechanical obstruction and has a non-syndromic hereditary basis. Mutations in the",
"    <em>",
"     PTHR1",
"    </em>",
"    gene in some families causes this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of failed tooth eruption include developmental defects of the teeth, abnormalities of bone or jaws, the presence of cysts or tumors, and syndromes. Asymmetry in the eruption pattern is a hallmark of these conditions and should prompt further evaluation and radiographic assessment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Teeth with developmental defects such as odontodysplasia form only rudimentary tooth appendages that can fail to erupt (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75284 \" href=\"UTD.htm?34/29/35280\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cysts, tumors (eg, hemangiomas, odontomas), or gingival overgrowth that form near developing tooth buds can prevent tooth eruption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30216?source=see_link\">",
"       \"Soft tissue lesions of the oral cavity in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of genetic conditions are associated with an increased prevalence of unerupted teeth (eg, hereditary enamel defects, amelogenesis imperfecta), as discussed below [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Primary failure of tooth eruption can be associated with mutations in the parathyroid hormone receptor",
"      <em>",
"       PTHR1",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     AGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmentally absent teeth can result from localized or generalized environmental insults (eg, trauma to a primary tooth, head and neck irradiation) or genetic disorders that affect the teeth in isolation or as part of a syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Congenitally missing teeth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of congenitally missing teeth varies by race and tooth type. Congenitally missing teeth are more common in the white population than in the black population (5 versus 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/16\">",
"     16",
"    </a>",
"    ] and in the permanent dentition than in the primary dentition. The maxillary lateral incisor and second premolar are the permanent teeth most frequently missing, and the mandibular central incisor is the primary tooth most frequently missing.",
"   </p>",
"   <p>",
"    Many children with missing teeth have a family member with a similar history. Several specific genetic mutations for missing teeth have been identified. For example, a missense mutation in the",
"    <em>",
"     MSX1",
"    </em>",
"    gene that codes for a transcription factor can cause the autosomal dominant trait of missing lateral incisors and third molars [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenitally missing teeth are a manifestation of numerous genetic syndromes. Some syndromes are associated with only a few missing teeth (eg, Down syndrome); other syndromes, such as the ectodermal dysplasias, are associated with multiple missing teeth (hypodontia) or complete absence of teeth (anodontia) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Young children suspected of having missing teeth or abnormal eruption patterns should be referred for complete dental evaluations. The diagnosis of congenitally missing teeth is confirmed by the absence of a full dental complement on dental radiographs. Genetic testing can then be offered to determine if the molecular basis of the child's condition is known and to help establish recurrence risk, risk of potential associated health problems (eg, axis inhibitor 2 [",
"    <em>",
"     AXIN2",
"    </em>",
"    ] mutations are associated with missing teeth and risk of colorectal cancer), and variability of expression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment for missing teeth varies and can require multiple therapeutic phases. Management of hypodontia or anodontia involves the use of prostheses or dental implants to replace the missing teeth and to enhance oral function and facial esthetics. Children who are missing multiple anterior teeth should receive their prostheses before beginning school [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/20\">",
"     20",
"    </a>",
"    ]. The optimal age for treatment is evaluated individually and determined by the extent of treatment needed and the child's ability to cooperate during the procedures and to maintain the appliances after placement. Dental implant procedures typically are delayed until the child reaches adolescence or early adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EXFOLIATION PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature exfoliation of primary teeth can be caused by local factors or systemic health problems. The eruption of permanent teeth can cause the exfoliation of adjacent primary teeth. For example, two primary incisors can exfoliate when the large permanent incisor begins to erupt; the exfoliation of multiple primary teeth in place of one permanent tooth often indicates a tooth-arch size discrepancy and usually heralds crowding in the permanent dentition.",
"   </p>",
"   <p>",
"    In addition, premature exfoliation of primary teeth can be associated with systemic conditions, such as hypophosphatasia, Langerhans histiocytosis, and cyclic neutropenia (",
"    <a class=\"graphic graphic_table graphicRef58443 \" href=\"UTD.htm?22/34/23084\">",
"     table 1",
"    </a>",
"    ). The lack of root resorption in the exfoliated primary tooth is a consistent clinical feature and an important clue to the diagnosis of systemic conditions that are associated with premature shedding of the primary teeth.",
"   </p>",
"   <p>",
"    Children with premature exfoliation of the primary teeth must be evaluated by their primary care providers for the systemic conditions associated with premature exfoliation because some of those conditions are life-threatening. The child also should be referred to a pediatric dentist for prompt initiation of appropriate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ENAMEL DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 100 known causes of enamel defects in humans have been identified. Defects in dental enamel are described in 25 to 80 percent of the general population and have both environmental and genetic causes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Environmental insults to enamel production that can affect matrix secretion or processing include exposure to trauma, infection, lead, mercury, and fluorine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fluorosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoride is used widely for the prevention of dental caries; however, excess fluoride consumption (greater than 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) can cause hypomineralization of dental enamel or fluorosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/26\">",
"     26",
"    </a>",
"    ]. The hypomineralization makes the teeth more susceptible to wear and breakage [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/27\">",
"     27",
"    </a>",
"    ]. Mild fluorosis is indicated by a white flecked or lacy appearance to the enamel (",
"    <a class=\"graphic graphic_picture graphicRef63417 \" href=\"UTD.htm?21/4/21583\">",
"     picture 2",
"    </a>",
"    ); severe fluorosis is indicated by a brown discoloration. The mechanism by which excessive fluoride consumption causes fluorosis is not fully understood and is likely complex [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Fluorosis can be prevented by appropriate fluoride supplementation and limitation of excessive fluoride consumption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33192?source=see_link\">",
"     \"Preventive dental care and counseling for infants and young children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hereditary enamel defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heritable conditions that cause enamel defects can be part of a syndrome or isolated to the enamel [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/24\">",
"     24",
"    </a>",
"    ]. Enamel defects associated with syndromic conditions vary substantially depending on the molecular defect and the gene's role in tooth formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tricho-dento-osseous syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tricho-dento-osseous syndrome is an autosomal dominant disorder caused by a mutation in the Distal-less 3, homeobox gene (",
"    <em>",
"     DLX3",
"    </em>",
"    ) and characterized by enamel hypoplasia that is smooth or pitted and elongation of the pulp chamber [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The",
"    <em>",
"     DLX3",
"    </em>",
"    gene functions as a transcription factor regulating the expression of other genes and is important in hair, tooth, and bone formation; children with this condition have kinky, curly hair at birth and develop dense or thickened bone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Junctional epidermolysis bullosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Junctional epidermolysis bullosa is an autosomal recessive disorder characterized by variable expression of skin fragility and blistering and varying severity of generalized enamel hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/32\">",
"     32",
"    </a>",
"    ]. The molecular defects that cause junctional epidermolysis bullosa involve genes that produce proteins essential to maintaining the integrity between the dermis and epidermis and are important in normal functioning of the ameloblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H13#H13\">",
"     \"The genodermatoses\", section on 'Epidermolysis bullosa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Amelogenesis imperfecta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amelogenesis imperfectas (AI) represent a group of heritable disorders with effects limited to the dental enamel; they include four clinically and genetically distinct types (",
"    <a class=\"graphic graphic_table graphicRef66836 \" href=\"UTD.htm?14/35/14908\">",
"     table 2",
"    </a>",
"    ) and 14 subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Mutations in several genes have now been associated with different AI types [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/36-44\">",
"     36-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amelogenin (",
"      <em>",
"       AMELX",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      Enamelin (",
"      <em>",
"       ENAM",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      Kallikrein 4 (",
"      <em>",
"       KLK4",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      Matrix metalloproteinase 20 (",
"      <em>",
"       MMP20",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      Family with sequence similarity 83, member H (",
"      <em>",
"       FAM83H",
"      </em>",
"      )",
"      <em>",
"      </em>",
"     </li>",
"     <li>",
"      WD repeat domain 72",
"      <em>",
"       (WDR72)",
"      </em>",
"      &ndash; Function not known",
"     </li>",
"     <li>",
"      Family with sequence similarity 20, member A",
"      <em>",
"       (FAM20A)",
"      </em>",
"      &ndash; Function not known",
"     </li>",
"     <li>",
"      Chromosome 4 open reading frame 26",
"      <em>",
"       (C4ORF26) &ndash;",
"      </em>",
"      Function not known",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mutations in different genes and allelic mutations of the same gene give rise to diverse enamel phenotypes ranging from hypoplastic, normal-colored enamel to brown, hypomineralized enamel that abrades from the teeth when they erupt into the oral cavity. The genotype-phenotype correlation of these AI defects is reviewed in detail at",
"    <a class=\"external\" href=\"file://www.dentistry.unc.edu/research/defects/pages/ai.htm\">",
"     Developmental Defects of the Teeth",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/45\">",
"     45",
"    </a>",
"    ]. The affected teeth can be extremely sensitive to thermal and chemical stimuli.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment of enamel defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of enamel defects depends upon the diagnosis and specific phenotype. For example, hypoplastic enamel that is well mineralized frequently can be treated with bonding procedures to protect and improve the appearance of the teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/46\">",
"     46",
"    </a>",
"    ]. On the other hand, teeth with severely hypomineralized enamel usually are treated with restorations that cover the entire crown (eg, stainless steel or resin crowns). Infants who have conditions known to be associated with enamel defects should be seen for dental evaluation and early intervention assessment before their first birthday.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DENTIN DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although environmental factors can affect the development of dentin, genetic factors have the primary influence. Dentin malformations that affect the form and function of the teeth occur in syndromic and nonsyndromic hereditary conditions.",
"   </p>",
"   <p>",
"    The dentinogenesis imperfectas and dentin dysplasias (",
"    <a class=\"graphic graphic_table graphicRef77566 \" href=\"UTD.htm?23/5/23644\">",
"     table 3",
"    </a>",
"    ) are classified using clinical, radiographic, and histopathologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/34,47\">",
"     34,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dentinogenesis imperfecta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dentinogenesis imperfecta (DI) is classified according to its association with or without other conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I &ndash; Associated with osteogenesis imperfecta and type I collagen defects; diminished pulp chambers are characteristic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"       \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type II &ndash; Not associated with osteogenesis imperfecta; diminished pulp chambers are characteristic.",
"     </li>",
"     <li>",
"      Type III &ndash; Often associated with the Brandywine triracial isolate (a genetically isolated triracial population from southern Maryland); large pulp chambers in young teeth are characteristic. This form is allelic to DI type II and is a really a phenotypic variant of DI type II and not a separate entity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all types of dentinogenesis imperfecta, the teeth have a variable, opalescent blue-gray to yellow-brown discoloration caused by the abnormally colored dentin shining through the translucent enamel (",
"    <a class=\"graphic graphic_picture graphicRef68896 \" href=\"UTD.htm?35/46/36576\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dentinogenesis imperfecta types II is an autosomal dominant condition and caused by mutations in the dentin sialophosphoprotein (",
"    <em>",
"     DSSP",
"    </em>",
"    ) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. It is interesting that the dental phenotypes of DI type I and type II are so similar. This is not surprising because DI type I is associated with type I collagen defects, and DI type II is associated with",
"    <em>",
"     DSPP",
"    </em>",
"    mutations, and type I collagen and",
"    <em>",
"     DSSP",
"    </em>",
"    interact during the development and mineralization of dentin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the defective dentin in children who have dentinogenesis imperfecta is often unable to support the enamel, the enamel frequently fractures from the teeth, leaving them susceptible to rapid wear and attrition. The teeth affected by dentinogenesis imperfecta can be worn down to the gingiva if left untreated.",
"   </p>",
"   <p>",
"    The treatment for dentinogenesis imperfecta depends upon the severity of discoloration and propensity for enamel loss. In children who do not have fracturing of the enamel, discoloration of the teeth can be treated with bonding; when severe fracturing of the enamel occurs, full coverage of the crowns typically is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Dentin dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of dentin dysplasia (",
"    <a class=\"graphic graphic_table graphicRef77566 \" href=\"UTD.htm?23/5/23644\">",
"     table 3",
"    </a>",
"    ). Dentin dysplasia type I is inherited as an autosomal dominant condition with a frequency of 1:100,000 persons. The molecular defect is unknown, but it causes a cyclical process of premature odontoblast death, new odontoblast recruitment, dentin deposition, and odontoblast death. The crowns of affected teeth appear normal, but radiographs show short, blunted roots and pulpal obliteration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/52\">",
"     52",
"    </a>",
"    ], resulting in teeth that are mobile, lost prematurely, and susceptible to abscess formation. No known treatment exists for this condition, but dental longevity can be increased by keeping occlusal forces to a minimum and avoiding orthodontic treatment for malalignment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dentin dysplasia type II also is inherited as an autosomal dominant trait. Mutations in the",
"    <em>",
"     DSPP",
"    </em>",
"    gene are associated with dentin dysplasia type II. Because they are caused by allelic mutations in the",
"    <em>",
"     DSPP",
"    </em>",
"    gene, the phenotype of dentin dysplasia type II and DI type II is identical in the primary teeth. They have yellow-brown to blue-gray discoloration and pulpal obliteration. The permanent dentition of children with dentin dysplasia type II is normally colored or only minimally discolored but has abnormal pulpal morphology and may be associated with pulp stones [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism leading to different phenotypes in the permanent dentitions of these two conditions is not fully understood. However, one study that involved clinical and genetic evaluation of 23 members of a four-generation kindred, including 10 members with dentin defects, suggested dentin dysplasia type II and DI type II represent the mild and severe forms, respectively, of the same disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/440/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of dentin dysplasia type II in the primary dentition is the same as that for dentinogenesis imperfecta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Systemic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic conditions can be associated with abnormal dentin formation as a result of molecular defects that interfere with dentin developmental pathways. For example, because dentin is 60 percent mineral, systemic conditions that are associated with defects of mineralization (eg, hypophosphatasia and vitamin-D-resistant rickets) affect dentin development. Other systemic conditions with dentin involvement include Ehlers Danlos syndrome, the mucopolysaccharidoses, and tumoral calcinosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distinguishing normal from pathological dental development requires careful evaluation of the patient, including medical, dental, and family history; clinical examination; radiographic evaluation; and possibly special laboratory tests. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Problems in tooth eruption include natal and neonatal teeth, premature eruption, and failed tooth eruption (impaction). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Eruption problems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of permanent tooth eruption failure is lack of space for eruption. Space deficiency frequently causes impaction of the third molars, the maxillary canines, and the mandibular second premolars. Inadequate space for eruption is treated with selective extraction of permanent teeth or orthodontic therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inadequate space'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Young children with failed eruption or abnormal eruption patterns should be referred for complete dental evaluation. Congenitally missing teeth are confirmed with dental radiographs. Genetic testing may help establish recurrence risk and risk of associated health problems. Management of missing teeth involves the use of prostheses or dental implants to replace the missing teeth and to enhance oral function and facial aesthetics. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Congenitally missing teeth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Premature exfoliation of primary teeth can be caused by local factors or systemic health problems. The lack of root resorption in the exfoliated primary tooth is an important clue that an underlying systemic health problem may exist. Children with premature exfoliation of the primary teeth must be evaluated to rule out serious systemic conditions (",
"      <a class=\"graphic graphic_table graphicRef58443 \" href=\"UTD.htm?22/34/23084\">",
"       table 1",
"      </a>",
"      ) and should be referred to a pediatric dentist for prompt initiation of appropriate dental therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Exfoliation problems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Defects in dental enamel have environmental (trauma, infection, fluoride) and genetic causes. Heritable conditions that cause enamel defects can be part of a syndrome (tricho-dento-osseous syndrome, junctional epidermolysis bullosa) or isolated to the enamel (eg, amelogenesis imperfecta). The treatment of enamel defects depends upon the diagnosis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Enamel defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dentin defects are primarily genetic; they occur in syndromic and nonsyndromic hereditary conditions. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Dentin defects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jones KL. Pattern of malformation differential diagnosis by anomalies. In: Smith's Recognizable patterns of Human Malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.865.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/2\">",
"      Mueller DT, Callanan VP. Congenital malformations of the oral cavity. Otolaryngol Clin North Am 2007; 40:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/3\">",
"      Decker E, Stellzig-Eisenhauer A, Fiebig BS, et al. PTHR1 loss-of-function mutations in familial, nonsyndromic primary failure of tooth eruption. Am J Hum Genet 2008; 83:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/4\">",
"      van der Linden FP. Theoretical and practical aspects of crowding in the human dentition. J Am Dent Assoc 1974; 89:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/5\">",
"      Brearley LJ, McKibben DH Jr. Ankylosis of primary molar teeth. I. Prevalence and characteristics. ASDC J Dent Child 1973; 40:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/6\">",
"      Steigman S, Koyoumdjisky-Kaye E, Matrai Y. Relationship of submerged deciduous molars to root resorption and development of permanent successors. J Dent Res 1974; 53:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/7\">",
"      Jensen BL, Kreiborg S. Development of the dentition in cleidocranial dysplasia. J Oral Pathol Med 1990; 19:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/8\">",
"      Smith NH. A histologic study of cementum in a case of cleidocranial dysostosis. Oral Surg Oral Med Oral Pathol 1968; 25:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/9\">",
"      Lee B, Thirunavukkarasu K, Zhou L, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 1997; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/10\">",
"      Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997; 89:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/11\">",
"      Trimble LD, West RA, McNeill RW. Cleidocranial dysplasia: comprehensive treatment of the dentofacial abnormalities. J Am Dent Assoc 1982; 105:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/12\">",
"      Frazier-Bowers SA, Simmons D, Wright JT, et al. Primary failure of eruption and PTH1R: the importance of a genetic diagnosis for orthodontic treatment planning. Am J Orthod Dentofacial Orthop 2010; 137:160.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/13\">",
"      Crawford PJ, Aldred MJ. Regional odontodysplasia: a bibliography. J Oral Pathol Med 1989; 18:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/14\">",
"      Collins MA, Mauriello SM, Tyndall DA, Wright JT. Dental anomalies associated with amelogenesis imperfecta: a radiographic assessment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/15\">",
"      Peters E, Cohen M, Altini M. Rough hypoplastic amelogenesis imperfecta with follicular hyperplasia. Oral Surg Oral Med Oral Pathol 1992; 74:87.",
"     </a>",
"    </li>",
"    <li>",
"     Dixon GH, Stewart RE. Genetic aspects of anomalous tooth development. In: Oral Facial Genetics, Stewart RE, Prescott GE (Eds), CV Mosby Company, St. Louis 1976. p.124.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/17\">",
"      Vastardis H, Karimbux N, Guthua SW, et al. A human MSX1 homeodomain missense mutation causes selective tooth agenesis. Nat Genet 1996; 13:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/18\">",
"      Crawford PJ, Aldred MJ, Clarke A. Clinical and radiographic dental findings in X linked hypohidrotic ectodermal dysplasia. J Med Genet 1991; 28:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/19\">",
"      Lammi L, Arte S, Somer M, et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 2004; 74:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/20\">",
"      Belanger GK. Early treatment considerations for oligodontia in ectodermal dysplasia: a case report. Quintessence Int 1994; 25:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/21\">",
"      Guckes AD, Brahim JS, McCarthy GR, et al. Using endosseous dental implants for patients with ectodermal dysplasia. J Am Dent Assoc 1991; 122:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/22\">",
"      Murray JJ, Shaw L. Classification and prevalence of enamel opacities in the human deciduous and permanent dentitions. Arch Oral Biol 1979; 24:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/23\">",
"      Seow WK. Enamel hypoplasia in the primary dentition: a review. ASDC J Dent Child 1991; 58:441.",
"     </a>",
"    </li>",
"    <li>",
"     Wright JT. Hereditary defects of enamel. In: Dental Enamel Formation to Destruction, Robinson C, Kirkham K, Shore R (Eds), CRC Press, Boca Raton, FL 1995. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/25\">",
"      Small BW, Murray JJ. Enamel opacities: prevalence, classifications and aetiological considerations. J Dent 1978; 6:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/26\">",
"      Richards A, Likimani S, Baelum V, Fejerskov O. Fluoride concentrations in unerupted fluorotic human enamel. Caries Res 1992; 26:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/27\">",
"      Fejerskov O, Manji F, Baelum V. The nature and mechanisms of dental fluorosis in man. J Dent Res 1990; 69 Spec No:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/28\">",
"      Bawden JW, Crenshaw MA, Wright JT, LeGeros RZ. Consideration of possible biologic mechanisms of fluorosis. J Dent Res 1995; 74:1349.",
"     </a>",
"    </li>",
"    <li>",
"     DenBesten PK, Giambro NJ. Dental fluorosis. In: Dental Enamel Formation to Destruction, Robinson C, Kirkham J, Shore R (Eds), CRC Press, Boca Raton, FL 1995. p.245.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/30\">",
"      Price JA, Bowden DW, Wright JT, et al. Identification of a mutation in DLX3 associated with tricho-dento-osseous (TDO) syndrome. Hum Mol Genet 1998; 7:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/31\">",
"      Wright JT, Kula K, Hall K, et al. Analysis of the tricho-dento-osseous syndrome genotype and phenotype. Am J Med Genet 1997; 72:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/32\">",
"      Wright JT, Hall KI, Deaton TG, Fine JD. Structural and compositional alteration of tooth enamel in hereditary epidermolysis bullosa. Connect Tissue Res 1996; 34:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/33\">",
"      Aberdam D, Aguzzi A, Baudoin C, et al. Developmental expression of nicein adhesion protein (laminin-5) subunits suggests multiple morphogenic roles. Cell Adhes Commun 1994; 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/34\">",
"      Witkop CJ Jr. Amelogenesis imperfecta, dentinogenesis imperfecta and dentin dysplasia revisited: problems in classification. J Oral Pathol 1988; 17:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/35\">",
"      B&auml;ckman B, Holmgren G. Amelogenesis imperfecta: a genetic study. Hum Hered 1988; 38:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/36\">",
"      Lagerstr&ouml;m M, Dahl N, Nakahori Y, et al. A deletion in the amelogenin gene (AMG) causes X-linked amelogenesis imperfecta (AIH1). Genomics 1991; 10:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/37\">",
"      Rajpar MH, Harley K, Laing C, et al. Mutation of the gene encoding the enamel-specific protein, enamelin, causes autosomal-dominant amelogenesis imperfecta. Hum Mol Genet 2001; 10:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/38\">",
"      Hart PS, Hart TC, Michalec MD, et al. Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta. J Med Genet 2004; 41:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/39\">",
"      Kim JW, Simmer JP, Hart TC, et al. MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J Med Genet 2005; 42:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/40\">",
"      Wright JT, Frazier-Bowers S, Simmons D, et al. Phenotypic variation in FAM83H-associated amelogenesis imperfecta. J Dent Res 2009; 88:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/41\">",
"      Lee SK, Seymen F, Kang HY, et al. MMP20 hemopexin domain mutation in amelogenesis imperfecta. J Dent Res 2010; 89:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/42\">",
"      El-Sayed W, Parry DA, Shore RC, et al. Mutations in the beta propeller WDR72 cause autosomal-recessive hypomaturation amelogenesis imperfecta. Am J Hum Genet 2009; 85:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/43\">",
"      O'Sullivan J, Bitu CC, Daly SB, et al. Whole-Exome sequencing identifies FAM20A mutations as a cause of amelogenesis imperfecta and gingival hyperplasia syndrome. Am J Hum Genet 2011; 88:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/44\">",
"      Parry DA, Brookes SJ, Logan CV, et al. Mutations in C4orf26, encoding a peptide with in vitro hydroxyapatite crystal nucleation and growth activity, cause amelogenesis imperfecta. Am J Hum Genet 2012; 91:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/45\">",
"      Wright JT, Hart PS, Aldred MJ, et al. Relationship of phenotype and genotype in X-linked amelogenesis imperfecta. Connect Tissue Res 2003; 44 Suppl 1:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/46\">",
"      Seow WK. Clinical diagnosis and management strategies of amelogenesis imperfectavariants. Pediatr Dent 1993; 15:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/47\">",
"      Shields ED, Bixler D, el-Kafrawy AM. A proposed classification for heritable human dentine defects with a description of a new entity. Arch Oral Biol 1973; 18:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/48\">",
"      Malmgren B, Lindskog S, Elgadi A, Norgren S. Clinical, histopathologic, and genetic investigation in two large families with dentinogenesis imperfecta type II. Hum Genet 2004; 114:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/49\">",
"      Dong J, Gu T, Jeffords L, MacDougall M. Dentin phosphoprotein compound mutation in dentin sialophosphoprotein causes dentinogenesis imperfecta type III. Am J Med Genet A 2005; 132A:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/50\">",
"      Rajpar MH, Koch MJ, Davies RM, et al. Mutation of the signal peptide region of the bicistronic gene DSPP affects translocation to the endoplasmic reticulum and results in defective dentine biomineralization. Hum Mol Genet 2002; 11:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/51\">",
"      He G, Ramachandran A, Dahl T, et al. Phosphorylation of phosphophoryn is crucial for its function as a mediator of biomineralization. J Biol Chem 2005; 280:33109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/52\">",
"      Kalk WW, Batenburg RH, Vissink A. Dentin dysplasia type I: five cases within one family. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/53\">",
"      Ranta H, Lukinmaa PL, Waltimo J. Heritable dentin defects: nosology, pathology, and treatment. Am J Med Genet 1993; 45:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/440/abstract/54\">",
"      Beattie ML, Kim JW, Gong SG, et al. Phenotypic variation in dentinogenesis imperfecta/dentin dysplasia linked to 4q21. J Dent Res 2006; 85:329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6276 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_440=[""].join("\n");
var outline_f0_27_440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ERUPTION PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Natal and neonatal teeth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abnormal eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Failed teeth eruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Inadequate space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ankylosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cleidocranial dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H885483159\">",
"      - Primary failure of eruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Congenitally missing teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EXFOLIATION PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ENAMEL DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fluorosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hereditary enamel defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tricho-dento-osseous syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Junctional epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Amelogenesis imperfecta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment of enamel defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DENTIN DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dentinogenesis imperfecta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Dentin dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Systemic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6276\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6276|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/17/5392\" title=\"diagnostic image 1\">",
"      Untreated early ankylosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/29/35280\" title=\"diagnostic image 2\">",
"      Regional odontodysplagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/52/27456\" title=\"picture 1\">",
"      Newborn with natal teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6276|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/4/21583\" title=\"picture 2\">",
"      Moderate fluorosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/46/36576\" title=\"picture 3\">",
"      Dentinogenesis imperfecta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6276|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/34/23084\" title=\"table 1\">",
"      Early primary tooth loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/35/14908\" title=\"table 2\">",
"      Amelogenesis imperfecta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/5/23644\" title=\"table 3\">",
"      Dentin dysplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39590?source=related_link\">",
"      Anatomy and development of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=related_link\">",
"      Evaluation and management of dental injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33192?source=related_link\">",
"      Preventive dental care and counseling for infants and young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30216?source=related_link\">",
"      Soft tissue lesions of the oral cavity in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_27_441="Supraventricular premature beats";
var content_f0_27_441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Supraventricular premature beats",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/441/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/441/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/441/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/441/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/27/441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular premature beats can originate from the atria (called atrial premature",
"    <span class=\"nowrap\">",
"     beats/complexes",
"    </span>",
"    or premature atrial",
"    <span class=\"nowrap\">",
"     beats/complexes)",
"    </span>",
"    or the atrioventricular node (called junctional premature",
"    <span class=\"nowrap\">",
"     beats/complexes",
"    </span>",
"    or premature junctional",
"    <span class=\"nowrap\">",
"     beats/complexes).",
"    </span>",
"    This topic will review the major clinical issues related to these abnormal beats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ATRIAL PREMATURE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An atrial premature beat (APB), also known as an atrial premature depolarization (APD), atrial premature complex (APC), premature atrial beat (PAB), or premature atrial complex (PAC), is a premature activation of the atria arising from a site other than the sinus node. They are observed on the surface electrocardiogram as a P wave that occurs relatively early in the cardiac cycle (ie, prematurely before the next sinus P wave should occur) and has a different morphology from the sinus P wave. Often the PR interval is different from that during sinus rhythm; it may be longer or shorter, depending upon the site of origin of the APB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34438?source=see_link&amp;anchor=H6#H6\">",
"     \"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias\", section on 'Premature atrial contractions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APBs may be asymptomatic or cause symptoms such as a sensation of \"skipping\" or palpitations. APBs are often single and isolated, but may be frequent and may occur in a bigeminal pattern. Although APBs have a wide array of manifestations, they are not life-threatening by themselves. In predisposed individuals, APBs may initiate supraventricular [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and, less commonly, ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Atrial fibrillation (AF) is the most common arrhythmia induced by APBs, particularly those that originate around the pulmonary vein [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/5\">",
"     5",
"    </a>",
"    ]. The presence and frequency of APBs has been shown to predict the development of AF after cardiac surgery and the recurrence of AF after cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link&amp;anchor=H3660617#H3660617\">",
"     \"The electrocardiogram in atrial fibrillation\", section on 'Atrial activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence and significance of APBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;APBs occur commonly in both young and elderly subjects and in those with and without significant heart disease; they should not be considered an abnormal finding [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/8\">",
"     8",
"    </a>",
"    ]. The prevalence of APBs is highly dependent upon the technique used for evaluation; 24-hour Holter monitoring is most accurate and is the preferred modality.",
"   </p>",
"   <p>",
"    The presence and frequency of APBs is dependent upon the presence of structural heart disease. They are particularly frequent in patients with mitral valve disease and in those with left ventricular dysfunction regardless of etiology. APBs also occur more frequently in association with noncardiac medical conditions such as acute and chronic pulmonary disease, chronic renal failure, and neurologic disorders. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiology of APBs'",
"    </a>",
"    below.) However, the high prevalence of APBs in the normal population makes such associations uncertain.",
"   </p>",
"   <p>",
"    The frequency and prevalence of APBs appears to increase with age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      APBs have been documented in the normal fetus and may be found in 4 to 14 percent of healthy newborn infants when using a 24-hour monitor [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. In one study of 134 newborns, for example 14 percent had APBs, but only 3 percent had more than 100 APBs in 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Holter monitoring studies performed in relatively young adult subjects without heart disease have demonstrated that approximately 10 to 73 percent have APBs, but only 2 percent have more than 100 APBs in a 24-hour period and less than one percent have very frequent APBs [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      APBs have been noted in 21 to 100 percent of healthy elderly subjects; 26 percent have more than 100 APBs per 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. In another study, APBs were documented in all non-acutely ill patients older than 90 years, 82 percent of whom had more than 100 APBs per 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The wide range in the reported prevalence of APBs in different populations may be related to the day-to-day variability in their prevalence and frequency. Although this has not been specifically studied, it is reasonable to assume that the variability is similar to that reported for ventricular premature depolarizations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9320?source=see_link\">",
"     \"Prevalence and evaluation of ventricular premature beats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    .) Circadian variation in the frequency of APBs may also occur, but there is significant interpatient variation.",
"   </p>",
"   <p>",
"    APBs may cause an increased risk of stroke. In a study of 402 men without myocardial infarction or stroke who were followed for 14 years, a high frequency of APBs without AF (&gt;214 per 24 hours) was associated with an increased risk of stroke in all men and in those with hypertension (relative risk 1.9 and 2.5 respectively compared to those without APBs or AF) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/21\">",
"     21",
"    </a>",
"    ]. Because only a single 24-hour ambulatory monitor was obtained, it is unclear how many patients developed AF during follow-up, and therefore the risk of stroke may have been due to undetected AF rather than a direct effect of APBs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanisms of APBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the mechanisms responsible for spontaneous APBs are not clear or well investigated, it seems likely that multiple mechanisms are responsible for APBs in different patients, depending upon the clinical situation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reentry within the atrium is probably the most common [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"       \"Reentry and the development of cardiac arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal automaticity may also be responsible for spontaneous APBs; support for this mechanism comes from microelectrode recordings identifying cells capable of exhibiting automaticity in a variety of areas of both the right and left atrium [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=see_link\">",
"       \"Enhanced cardiac automaticity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Triggered activity is another potential mechanism for APBs. Atrial fibers located in the region around the coronary sinus and cells within the coronary sinus display afterdepolarizations that mediate triggered activity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Etiology of APBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because APBs occur frequently in subjects with normal hearts, it is difficult to establish a definite relationship to other disorders or to delineate the factors that predispose to these extra beats. Furthermore, the incidence of APBs is variable in different forms of structural heart disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral valve prolapse &mdash; The reported prevalence among patients with mitral valve prolapse varies widely from 35 to 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. When matched to control subjects with similar symptoms, however, patients with mitral valve prolapse do not appear to have an excess prevalence of APBs [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"       \"Arrhythmic complications of mitral valve prolapse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coronary heart disease &mdash; Patients with an acute myocardial infarction have an early increase in the frequency of APBs, with an incidence ranging from 25 to 81 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. One study noted a mean of 9 to 14 APBs per hour on day 1 of infarction, which decreased to 1 to 2 APBs per hour on day 10 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/27\">",
"       27",
"      </a>",
"      ]. This increase in atrial arrhythmia frequency in the setting of acute myocardial infarction may be related to multiple factors, including concomitant involvement of the atrium",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the sinus node, reduced left ventricular function and congestive heart failure with left or right atrial dilation, autonomic influences, iatrogenic factors (eg, administration of digitalis or sympathomimetic agents), and pericarditis.",
"      <br/>",
"      <br/>",
"      Among patients with known or suspected coronary heart disease, APBs can be induced during exercise testing. In a report of 5375 such patients, APBs occurred in 24 percent during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/29\">",
"       29",
"      </a>",
"      ]. The development of APBs was not predictive of long-term rates of cardiac death or revascularization after adjustment for clinical and exercise variables. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H8#H8\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Atrial arrhythmias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other heart diseases &mdash; The frequency of APBs appears to be increased in mitral stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/30\">",
"       30",
"      </a>",
"      ], hypertrophic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/31\">",
"       31",
"      </a>",
"      ], and any condition that results in an elevation in pressure in or dilatation of the right or left atrium including cardiomyopathy, valvular heart disease, and activation of the sympathetic nervous system. Pericardial inflammation may also increase the incidence of atrial arrhythmias, but this remains unproven.",
"     </li>",
"     <li>",
"      Toxins or chemicals &mdash; Smoking, alcohol, and coffee are considered potential precipitants of APBs [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. Smoking and alcohol are known to increase sympathetic tone, which may affect the frequency of APBs. Although caffeine has clear electrophysiologic effects on the atria, the association with APBs is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/34\">",
"       34",
"      </a>",
"      ]. Nevertheless, there are patients who note a relationship of palpitations to caffeine intake.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      , another methylxanthine compound, also may increase APB frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Miscellaneous conditions &mdash; APBs may be more common in a variety of other medical conditions, such as acute and chronic pulmonary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/37\">",
"       37",
"      </a>",
"      ], chronic renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/38\">",
"       38",
"      </a>",
"      ], and neurologic disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/39\">",
"       39",
"      </a>",
"      ]. There is conflicting evidence on the frequency of APBs with stress and fatigue [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ECG manifestation and diagnosis of APBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;APBs may have a variety of manifestations on the electrocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34438?source=see_link\">",
"     \"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of an APB is made when a P wave with a morphology different from that of the sinus P wave (inverted or biphasic) occurs earlier than the anticipated sinus P wave (",
"    <a class=\"graphic graphic_waveform graphicRef66489 \" href=\"UTD.htm?13/0/13312\">",
"     waveform 1",
"    </a>",
"    ). If the ectopic focus is near the sinus node the P wave may be similar to that of the sinus P. However, every lead should be examined as subtle differences in morphology may be present.",
"   </p>",
"   <p>",
"    One of the following ECG patterns may arise due to variable ventricular conduction of the APB:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A normal QRS complex and a normal or short PR interval",
"     </li>",
"     <li>",
"      A normal QRS complex and a prolonged PR interval",
"     </li>",
"     <li>",
"      A conducted but aberrant (widened) QRS complex",
"     </li>",
"     <li>",
"      No QRS complex (nonconducted APB) (",
"      <a class=\"graphic graphic_waveform graphicRef77154 \" href=\"UTD.htm?38/54/39790\">",
"       waveform 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of factors affect the characteristics of an APB and its conduction to the ventricle. As an example, with increasing prematurity of an APB, the atrioventricular (AV) node conduction time progressively increases (and the PR interval increases) until the effective refractory period of the AV node is reached and the APB is blocked within the node and nonconducted. A conduction \"gap,\" concealed conduction, and supernormal conduction may also affect the conduction of an APB to the ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the site of origin of an APB can affect its conduction through the AV node, and its P wave morphology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An APB originating in the low right atrium near the AV node may result in a short PR interval (&lt;120 msec) and may even be mistaken for a junctional premature depolarization. However, intracardiac recordings of these types of APBs reveal a normal AH interval, suggesting that they arise outside the AV node.",
"     </li>",
"     <li>",
"      A negative P wave in the inferior leads, particularly aVF, suggests a low atrial focus, while a negative P wave in lead I suggests a right atrial origin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AV nodal conduction time, and therefore the PR interval, may also differ depending on the input pathway to the AV node. APBs that originate from the left atrium typically have shorter conduction times than those originating from the right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nonconducted APB, especially one that may be obscured by the T wave, may give the false appearance of a sinus pause (",
"    <a class=\"graphic graphic_waveform graphicRef77154 \" href=\"UTD.htm?38/54/39790\">",
"     waveform 2",
"    </a>",
"    ). Evaluation of multiple leads may be required to detect the APB, since it may cause a discernible deflection, seen as a deformity of the normal T wave, in only one or a few ECG leads. The normal T wave should have a smooth upstroke and downstroke so that any deformity may be a superimposed P wave. A nonconducted APB that occurs late in the cardiac cycle may give the appearance of a Mobitz type II second degree heart block.",
"   </p>",
"   <p>",
"    Early APBs may also impinge upon the refractory period of the His-Purkinje conduction system and lead to variable degrees of aberrant conduction. Such aberrancy is a common phenomenon. In one study of 1306 APBs in 201 patients, for example, aberrantly conducted APBs were three times more frequent than normally conducted APBs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/45\">",
"     45",
"    </a>",
"    ]. In general, right bundle branch block aberrancy is more common than left bundle branch block aberrancy because of the longer refractory period of the right bundle branch [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/46\">",
"     46",
"    </a>",
"    ]. Infrequently, the beat after the postextrasystolic interval is conducted aberrantly, a finding similar to that observed in atrial fibrillation with a long-short cycle (Ashman phenomenon). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link&amp;anchor=H3660617#H3660617\">",
"     \"The electrocardiogram in atrial fibrillation\", section on 'Atrial activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Much attention has been paid to the postextrasystolic interval in the diagnosis of an APB. The postextrasystolic interval has been studied most carefully in the electrophysiology laboratory, and four zones have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An APB that occurs relatively late in the cardiac cycle may not reach the sinus node and will therefore not reset the sinus node (zone of collision or interference). In this case, a fully compensatory pause may be noted, ie, although the sinus node fires, it is not transmitted through the AV node which is refractory and hence the RR interval surrounding the APB is equivalent to twice the underlying sinus rate.",
"     </li>",
"     <li>",
"      More commonly, an APB will depolarize the sinus node and reset it (zone of reset). In this setting, a fully compensatory pause is not seen and a less than full compensatory pause occurs. On occasion, there may be a pause that is longer than a full compensatory pause. In addition, the typical features of reset may not be observed if there is sinus exit block, which may occur with early APBs in normal subjects. When the pause is longer than a full compensatory pause, there may be underlying sinus node disease or dysfunction (ie, sick sinus syndrome).",
"     </li>",
"     <li>",
"      A very early APB may find the sinus node refractory, giving rise to an interpolated APB (zone of interpolation) or sinus echoes (zone of sinus echoes). These types of responses are the least common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, APBs may depolarize and transiently depress sinus node function or automaticity (ie, sinus node arrest or pause), thereby causing a post-APB interval that is longer than the previously noted sinus cycle length. This is often seen in patients with underlying sinus node disease (ie, sick sinus syndrome). In this setting, there is a postextrasystolic pause that is longer than a fully compensatory interval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electrophysiology of APBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no indications for performing electrophysiology studies in patients with APBs. Electrophysiologic findings include an atrial activation sequence that is different from the sinus activation sequence, and normal conduction through the AV node and His-Purkinje system (",
"    <a class=\"graphic graphic_waveform graphicRef70505 \" href=\"UTD.htm?37/11/38065\">",
"     waveform 3",
"    </a>",
"    ). However, functional bundle branch block may be seen, leading to HV interval prolongation. Nonconducted APBs typically demonstrate block at the AV node.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symptoms associated with APBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most subjects with APBs are asymptomatic (as are most subjects with ventricular premature beats). However, APBs may lead to palpitations (when there is a pause and increased left ventricular inotropy resulting from an increased in stroke volume and the Starling effect; ie, post extrasystolic potentiation) or the sensation of skipped beats which may be due to nonconducted APBs or ineffective contraction resulting from poor filling of the left ventricle during the premature beat. Atrial bigeminy with nonconducted APBs may lead to ventricular rates approaching 40",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    possibly leading to symptoms related to the bradyarrhythmia (",
"    <a class=\"graphic graphic_waveform graphicRef72122 \" href=\"UTD.htm?42/48/43789\">",
"     waveform 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination in patients with APBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the peripheral pulse will demonstrate either premature pulse waves or pauses related to APBs. Early APBs may lead to cannon A waves on the jugular venous pulsations as they may occur while the AV valves are still closed from the previous ventricular systole. This finding may be particularly helpful in differentiating early nonconducted APBs from sinus pauses. Auscultation of the heart may detect early heart sounds or pauses. APBs may also lead to changes in the intensity or timing of a variety of cardiac murmurs (such as those due to mitral valve prolapse) due to the reduction in diastolic filling time and a reduction in ventricular volumes. These changes may be reversed with the post extrasystolic beat, since there is an increase in ventricular volume due to the pause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recommendations for therapy for APBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;No therapy is required for APBs in the asymptomatic individual. For patients with symptomatic APBs, symptoms may be alleviated by reassuring the patient of the benign nature of APBs and by discontinuing potential precipitating habits such as smoking, coffee intake, alcohol intake, and stress.",
"   </p>",
"   <p>",
"    If necessary, medical therapy should begin with a beta blocker if no contraindication exists for its use. Beta blockers can reduce the symptoms related to APBs and may reduce their frequency, particularly if they are due to enhanced automaticity related to enhanced sympathetic output. However, the response to beta blockers is inconsistent and variable.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    , calcium channel blockers, and type IB antiarrhythmic agents have not been clearly shown to be beneficial in patients with symptomatic APBs. By comparison, type IA, type IC, and type III antiarrhythmic agents can diminish the frequency of APBs in the symptomatic patient. These drugs may also suppress APBs that precipitate or trigger other supraventricular arrhythmias including atrial fibrillation, atrial flutter, atrioventricular nodal reentrant tachycardia, or atrioventricular reentrant tachycardia. Beta blockers do not suppress APBs but may be useful to reduce symptoms by reducing the increased inotropy seen with the post extrasystolic beat (ie, post extrasystolic potentiation).",
"   </p>",
"   <p>",
"    Although controlled studies have not been performed with many of these agents, several reports describe their successful use [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. However, administration of these agents must be balanced with the risk of proarrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     JUNCTIONAL PREMATURE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Junctional premature beats, also called junctional premature depolarizations or junctional premature complexes (JPBs, JPDs, or JPCs) arise within the AV junction. Although the origin of early junctional depolarizations is still debated, they may arise in the AV node or in the His bundle. JPBs may conduct both anterograde to the ventricles and retrograde to the atrium, or may demonstrate anterograde",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retrograde conduction block.",
"   </p>",
"   <p>",
"    As with APBs, JPBs occur in normal and abnormal hearts, the young and the old. They may cause no symptoms or lead to symptoms such as palpitations. JPBs may mimic APBs and ventricular premature depolarizations in both appearance and symptoms. More importantly, JPBs have achieved notoriety due to their ability to give rise to \"pseudo-AV block\" [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevalence and significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;JPBs occur less commonly than both atrial and ventricular premature depolarizations. Their prevalence, however, has not been well studied which may be due in part from difficulty in making the correct diagnosis. In addition, many studies combine JPBs and APBs into one category of supraventricular premature beats.",
"   </p>",
"   <p>",
"    The frequency of junctional premature depolarizations varies with study population. In one study that examined the ECGs of 122,043 healthy individuals (age 16 to 50 years), JPBs were noted in 0.2 percent with an equal distribution in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/8\">",
"     8",
"    </a>",
"    ]. In comparison, JPBs have been noted in 3 percent of active elderly subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/16\">",
"     16",
"    </a>",
"    ] and up to 6 to 16 percent of patients with an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the mechanisms responsible for JPBs are not clear or well investigated, they are most likely due to abnormal automaticity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=see_link\">",
"     \"Enhanced cardiac automaticity\"",
"    </a>",
"    .) The AV nodal junction has been divided into three regions based upon electrophysiologic properties: the N, AN, and NH zones [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The N or central region displays maximal conduction slowing.",
"     </li>",
"     <li>",
"      The AN region has properties intermediate between those of the adjacent rapidly conducting atrial fibers and those in the N region",
"     </li>",
"     <li>",
"      The NH region is a transitional zone between the N region and the His bundle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exact site of the zonal origin of JPBs has been debated. One study, for example, identified diastolic depolarization in the N region of the AV node, suggesting automaticity in this area as a potential mechanism for JPBs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/57\">",
"     57",
"    </a>",
"    ]. Other investigators have suggested that these premature depolarizations are due to automaticity in either the NH region of the AV node or in the His bundle [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Triggered activity due to delayed afterdepolarizations has been suggested as a potential explanation for junctional escape rhythms and may also be a potential mechanism for the genesis of JPBs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/59\">",
"     59",
"    </a>",
"    ]. While the AV junction is capable of mediating reentry (eg, in an AV junctional reentrant tachycardia), this is not a likely mechanism for early junctional depolarizations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;JPBs may occur in subjects with normal or abnormal hearts. Their presence may be increased by hypokalemia, digitalis toxicity, chronic lung disease, and acute myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     ECG manifestation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;JPBs may have a variety of manifestations on the surface electrocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34438?source=see_link\">",
"     \"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias\"",
"    </a>",
"    .) They are most often detected when there is a premature beat with a normal QRS complex",
"    <strong>",
"     and",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A P wave with a PR interval that is too short to be considered to be conducted through the AV node (",
"      <a class=\"graphic graphic_waveform graphicRef62336 \" href=\"UTD.htm?31/12/31936\">",
"       waveform 5",
"      </a>",
"      ). Although the upper limits of the conduction times (PR interval) consistent with JPBs have not been defined, a premature complex with a PR interval less than 90 msec is unlikely to reflect a conducted APB.",
"     </li>",
"     <li>",
"      No P wave. The absence of a P wave may be due to burial of the wave within the QRS complex or the lack of retrograde atrial activation.",
"     </li>",
"     <li>",
"      A P wave that occurs at the terminal portion of the QRS complex, within the ST segment, or on the T wave, depending upon the rate of retrograde conduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The location of the P wave relative to the QRS complex provides no definitive information regarding the site of origin within the AV junction; it is simply a manifestation of the relative anterograde and retrograde conduction velocities.",
"   </p>",
"   <p>",
"    Like APBs, JPBs may conduct anterogradely with a functional or rate-related bundle branch block. In this setting, they may be indistinguishable on the ECG from premature ventricular depolarizations. In this setting, only intracardiac recording of His bundle activation will differentiate between these two possibilities, since a bundle of His deflection precedes a JPB but not a premature ventricular depolarization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    JPBs may also conduct retrogradely to the atrium and demonstrate conduction block to the ventricles. In this setting, they are similar to APBs and are indistinguishable from nonconducted APBs on the surface ECG. Differentiating between these possibilities is frequently made more difficult by the limited number of leads available for analysis and the potential obscuration of atrial activation (P wave) by the preceding T wave.",
"   </p>",
"   <p>",
"    Finally, JPBs may fail to conduct both antegrade to the ventricles and retrograde to the atria, in which case they are \"concealed\" JPBs. Such lack of conduction may have no effect on the surface ECG or may be manifest as either sudden prolongation of the PR interval (first degree AV block) for a single beat or Mobitz type I (Wenckebach) or Mobitz type II second-degree AV block. Concealed junctional bigeminy may give rise to 2:1 AV block&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitive differentiation between concealed JPBs leading to the appearance of Mobitz II second-degree AV block versus actual Mobitz II second-degree AV block is virtually impossible on the surface electrocardiogram. However, it is an important distinction because of the risk of progression to complete heart block associated with Mobitz II block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility of concealed JPBs masquerading as AV block should be considered in a patient with a normal QRS duration and evidence of manifest or conducted JPBs. The P wave morphology of JPBs generally reflects retrograde activation of the atria via the AV node. Thus, the P wave is generally inverted in ECG leads II, aVF and V5-V6, upright in aVR, flat or biphasic in lead I, and usually upright in V1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;JPBs generally do not require invasive electrophysiologic investigation unless there is a question of infra-His conduction disease, as in the patient with \"pseudo AV block\" who may possibly have Mobitz II second-degree AV block. JPBs occur occasionally during routine electrophysiology studies, and the diagnosis is made when a premature His bundle activation occurs (",
"    <a class=\"graphic graphic_figure graphicRef60996 \" href=\"UTD.htm?27/36/28225\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is anterograde conduction, the HV interval will be either the same as baseline or prolonged (ruling out a ventricular origin of the premature beat).",
"     </li>",
"     <li>",
"      If there is retrograde activation of the atria, atrial activation will occur following the His bundle activation. The HA conduction time may be variable depending upon the site of origin within the AV junction and the retrograde conduction properties of the AV node. The activation sequence will typically reveal earliest atrial activation in the His bundle recording, spreading to the high right atrium and left atrium. It may be difficult to differentiate JPBs from APBs arising from the low septal right atrium with rapid AV nodal conduction times.",
"     </li>",
"     <li>",
"      The diagnosis of a concealed JPB is made when an isolated His bundle activation is seen without atrial or ventricular activation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most subjects with JPBs, like most subjects with APBs, are asymptomatic. However, JPBs may lead to symptoms of palpitations or the sensation of skipped beats. The sensation of skipped beats may be due to concealed JPBs or ineffective contraction due to poor filling of the left ventricle during the premature beat. Concealed JPBs that lead to second degree AV block may be associated with symptoms of lightheadedness or near syncope, particularly if they occur in a bigeminal pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the peripheral pulse will demonstrate either a premature pulse wave or pauses related to JPBs. Auscultation of the heart may detect pauses or early heart sounds. As with APBs, JPBs can alter the timing or intensity of cardiac murmurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recommendation for therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No therapy is required for JPBs in the asymptomatic individual. Due to their low frequency and even rarer incidence of significant symptoms, the appropriate treatment of symptomatic JPBs has not been evaluated. Reassurance of the benign nature of this rhythm abnormality may alleviate symptoms. Patients in whom JPBs are precipitated by specific factors should discontinue or control exposure to offending agents.",
"   </p>",
"   <p>",
"    For patients with persistent, limiting symptoms, further therapeutic options (similar to those for APBs) include beta blockers and calcium channel blockers. For patients refractory to these therapies, class IA, IC, or III antiarrhythmic agents may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/441/abstract/61\">",
"     61",
"    </a>",
"    ]. However, treatment with these agents must be balanced against the risk for proarrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is unlikely to control symptomatic JPBs.",
"   </p>",
"   <p>",
"    Patients with concealed JPBs giving rise to pseudo-AV block and symptomatic bradycardia should be treated with agents that will suppress the JPBs rather than pacemaker implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5230411\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An atrial premature beat (APB) is a premature activation of the atria arising from a site other than the sinus node, resulting in a P wave on the surface electrocardiogram (ECG) that occurs relatively early in the cardiac cycle (ie, prematurely before the next sinus P wave should occur) and has a different morphology from the sinus P wave. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Atrial premature beats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of an APB is made when a P wave with a morphology different from that of the sinus P wave (inverted or biphasic) occurs earlier than the anticipated sinus P wave (",
"      <a class=\"graphic graphic_waveform graphicRef66489 \" href=\"UTD.htm?13/0/13312\">",
"       waveform 1",
"      </a>",
"      ). If the ectopic focus is near, the sinus node the P wave may be similar to that of the sinus P. However, every lead should be examined as subtle differences in morphology may be present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'ECG manifestation and diagnosis of APBs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence and frequency of APBs is dependent upon the presence of structural heart disease. They are particularly frequent in patients with mitral valve disease and in those with left ventricular dysfunction regardless of etiology. The frequency and prevalence of APBs also appears to increase with age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence and significance of APBs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most subjects with APBs are asymptomatic (as are most subjects with ventricular premature beats). However, APBs may lead to palpitations (when there is a pause and increased left ventricular inotropy resulting from an increase in stroke volume and the Starling effect; ie, post extrasystolic potentiation) or the sensation of skipped beats which may be due to nonconducted APBs or ineffective contraction resulting from poor filling of the left ventricle during the premature beat. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Symptoms associated with APBs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No therapy is required for APBs in the asymptomatic individual. For patients with symptomatic APBs, symptoms may be alleviated by reassuring the patient of the benign nature of APBs and by discontinuing potential precipitating habits such as smoking, coffee intake, alcohol intake, and stress. If necessary, medical therapy should begin with a beta blocker which can reduce the symptoms related to APBs and may reduce their frequency. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Recommendations for therapy for APBs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Junctional premature beats (JPBs) arise within the AV junction. Although the origin of JPBs is still debated, they may arise in the AV node or in the His bundle. JPBs may conduct both anterograde to the ventricles and retrograde to the atrium, or may demonstrate anterograde",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      retrograde conduction block. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Junctional premature beats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      JPBs may have a variety of manifestations on the surface electrocardiogram. They are most often detected when there is a premature beat with a normal QRS complex and either a P wave with a PR interval that is too short to be considered to be conducted through the AV node (",
"      <a class=\"graphic graphic_waveform graphicRef62336 \" href=\"UTD.htm?31/12/31936\">",
"       waveform 5",
"      </a>",
"      ), no P wave, or a P wave that occurs within the QRS complex or ST-T waves. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'ECG manifestation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      JPBs may occur in subjects with normal or abnormal hearts. Their presence may be increased by hypokalemia, digitalis toxicity, chronic lung disease, and acute myocardial infarction. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most subjects with JPBs, like most subjects with APBs, are asymptomatic. However, JPBs may lead to symptoms of palpitations or the sensation of skipped beats. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Associated symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No therapy is required for JPBs in the asymptomatic individual. For patients with symptomatic JPBs, symptoms may be alleviated by reassuring the patient of the benign nature of JPBs and by discontinuing potential precipitating factors. If necessary, medical therapy should begin with a beta blocker which can reduce the symptoms related to JPBs and may reduce their frequency. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Recommendation for therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/1\">",
"      Bennett MA, Pentecost BL. The pattern of onset and spontaneous cessation of atrial fibrillation in man. Circulation 1970; 41:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/2\">",
"      Durrer D, Schoo L, Schuilenburg RM, Wellens HJ. The role of premature beats in the initiation and the termination of supraventricular tachycardia in the Wolff-Parkinson-White syndrome. Circulation 1967; 36:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/3\">",
"      Nallasivan M, Appel RA, Welch WJ, Bauernfeind RA. Ventricular tachycardia due to bundle branch reentry: induction by spontaneous atrial premature beats. Am Heart J 1988; 116:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/4\">",
"      Berman ND. Ventricular tachycardia initiated by both normally and aberrantly conducted atrial premature beats. Pacing Clin Electrophysiol 1980; 3:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/5\">",
"      Ha&iuml;ssaguerre M, Ja&iuml;s P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/6\">",
"      Jid&eacute;us L, Kesek M, Joachimsson PO, et al. The role of premature atrial contractions as the main triggers of postoperative atrial fibrillation. J Electrocardiol 2006; 39:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/7\">",
"      Maounis T, Kyrozi E, Katsaros K, et al. The prognostic significance of atrial arrhythmias recorded early after cardioversion for atrial fibrillation. Pacing Clin Electrophysiol 2001; 24:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/8\">",
"      HISS RG, LAMB LE. Electrocardiographic findings in 122,043 individuals. Circulation 1962; 25:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/9\">",
"      Romhilt DW, Chaffin C, Choi SC, Irby EC. Arrhythmias on ambulatory electrocardiographic monitoring in women without apparent heart disease. Am J Cardiol 1984; 54:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/10\">",
"      Itskovitz J, Timor-Tritsch I, Brandes JM. Intrauterine fetal arrhythmia: atrial premature beats. Int J Gynaecol Obstet 1979; 16:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/11\">",
"      Southall DP, Orrell MJ, Talbot JF, et al. Study of cardiac arrhythmias and other forms of conduction abnormality in newborn infants. Br Med J 1977; 2:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/12\">",
"      Southall DP, Richards J, Mitchell P, et al. Study of cardiac rhythm in healthy newborn infants. Br Heart J 1980; 43:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/13\">",
"      Sobotka PA, Mayer JH, Bauernfeind RA, et al. Arrhythmias documented by 24-hour continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease. Am Heart J 1981; 101:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/14\">",
"      Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/15\">",
"      Folarin VA, Fitzsimmons PJ, Kruyer WB. Holter monitor findings in asymptomatic male military aviators without structural heart disease. Aviat Space Environ Med 2001; 72:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/16\">",
"      Camm AJ, Evans KE, Ward DE, Martin A. The rhythm of the heart in active elderly subjects. Am Heart J 1980; 99:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/17\">",
"      Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: detection by 24-hour ambulatory electrocardiography. Chest 1982; 81:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/18\">",
"      Rossi A. Twenty-four-hour electrocardiographic study in the active very elderly. Cardiology 1987; 74:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/19\">",
"      Toivonen L. Spontaneous variability in the frequency of ventricular premature complexes over prolonged intervals and implications for antiarrhythmic treatment. Am J Cardiol 1987; 60:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/20\">",
"      Pratt CM, Delclos G, Wierman AM, et al. The changing base line of complex ventricular arrhythmias. A new consideration in assessing long-term antiarrhythmic drug therapy. N Engl J Med 1985; 313:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/21\">",
"      Engstrom G, Hedblad B, Juul-Moller S, et al. Cardiac arrhythmias and stroke: increased risk in men with high frequency of atrial ectopic beats. Stroke 2001; 32:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/22\">",
"      WALLACE AG, DAGGETT WM. RE-EXCITATION OF THE ATRIUM. \"THE ECHO PHENOMENON\". Am Heart J 1964; 68:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/23\">",
"      DE CARVALHO AP, DE MELLO WC, HOFFMAN BF. Electrophysiological evidence for specialized fiber types in rabbit atrium. Am J Physiol 1959; 196:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/24\">",
"      Wit AL, Cranefield PF. Triggered and automatic activity in the canine coronary sinus. Circ Res 1977; 41:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/25\">",
"      Kramer HM, Kligfield P, Devereux RB, et al. Arrhythmias in mitral valve prolapse. Effect of selection bias. Arch Intern Med 1984; 144:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/26\">",
"      Savage DD, Levy D, Garrison RJ, et al. Mitral valve prolapse in the general population. 3. Dysrhythmias: the Framingham Study. Am Heart J 1983; 106:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/27\">",
"      Rechavia E, Strasberg B, Mager A, et al. The incidence of atrial arrhythmias during inferior wall myocardial infarction with and without right ventricular involvement. Am Heart J 1992; 124:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/28\">",
"      Zoni Berisso M, Ferroni A, De Caro E, et al. Clinical significance of supraventricular tachyarrhythmias after acute myocardial infarction. Eur Heart J 1986; 7:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/29\">",
"      Bunch TJ, Chandrasekaran K, Gersh BJ, et al. The prognostic significance of exercise-induced atrial arrhythmias. J Am Coll Cardiol 2004; 43:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/30\">",
"      Ramsdale DR, Arumugam N, Singh SS, et al. Holter monitoring in patients with mitral stenosis and sinus rhythm. Eur Heart J 1987; 8:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/31\">",
"      Lazzeroni E, Domenicucci S, Finardi A, et al. Severity of arrhythmias and extent of hypertrophy in hypertrophic cardiomyopathy. Am Heart J 1989; 118:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/32\">",
"      Davis MJ, Hockings BE, el Dessouky MA, et al. Cigarette smoking and ventricular arrhythmia in coronary heart disease. Am J Cardiol 1984; 54:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/33\">",
"      Ettinger PO, Wu CF, De La Cruz C Jr, et al. Arrhythmias and the \"Holiday Heart\": alcohol-associated cardiac rhythm disorders. Am Heart J 1978; 95:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/34\">",
"      Dobmeyer DJ, Stine RA, Leier CV, et al. The arrhythmogenic effects of caffeine in human beings. N Engl J Med 1983; 308:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/35\">",
"      Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest 1991; 99:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/36\">",
"      Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990; 98:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/37\">",
"      Kleiger RE, Senior RM. Longterm electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest 1974; 65:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/38\">",
"      Kimura K, Tabei K, Asano Y, Hosoda S. Cardiac arrhythmias in hemodialysis patients. A study of incidence and contributory factors. Nephron 1989; 53:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/39\">",
"      Di Pasquale G, Pinelli G, Andreoli A, et al. Holter detection of cardiac arrhythmias in intracranial subarachnoid hemorrhage. Am J Cardiol 1987; 59:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/40\">",
"      Stamler JS, Goldman ME, Gomes J, et al. The effect of stress and fatigue on cardiac rhythm in medical interns. J Electrocardiol 1992; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/41\">",
"      Wu D, Denes P, Dhingra R, Rosen KM. Nature of the gap phenomenon in man. Circ Res 1974; 34:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/42\">",
"      Langendorf R. Concealed A-V conduction: The effect of blocked impulses on the formation and conduction of subsequent impulses. Am Heart J 1974; 35:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/43\">",
"      PICK A, LANGENDORF R, KATZ LN. The supernormal phase of atrioventricular conduction. I. Fundamental mechanisms. Circulation 1962; 26:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/44\">",
"      Batsford WP, Akhtar M, Caracta AR, et al. Effect of atrial stimulation site on the electrophysiological properties of the atrioventricular node in man. Circulation 1974; 50:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/45\">",
"      Berliner K, Lewithin L. Auricular premature systole. Am Heart J 1945; 29:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/46\">",
"      MOE GK, MENDEZ C, HAN J. ABERRANT A-V IMPULSE PROPAGATION IN THE DOG HEART: A STUDY OF FUNCTIONAL BUNDLE BRANCH BLOCK. Circ Res 1965; 16:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/47\">",
"      Strauss HC, Saroff AL, Bigger JT Jr, Giardina EG. Premature atrial stimulation as a key to the understanding of sinoatrial conduction in man. Presentation of data and critical review of the literature. Circulation 1973; 47:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/48\">",
"      Dhingra RC, Wyndham C, Denes P, et al. Sinus nodal responses to atrial extrastimuli in patients without apparent sinus node disease. Am J Cardiol 1975; 36:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/49\">",
"      Arif M, Laidlaw JC, Oshrain C, et al. A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias. Angiology 1983; 34:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/50\">",
"      Carrasco HA, Vicu&ntilde;a AV, Molina C, et al. Effect of low oral doses of disopyramide and amiodarone on ventricular and atrial arrhythmias of chagasic patients with advanced myocardial damage. Int J Cardiol 1985; 9:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/51\">",
"      Coumel P, Leclercq JF, Assayag P. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol 1984; 54:60D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/52\">",
"      Rosen KM, Rahimtoola SH, Gunnar RM. Pseudo A-V block secondary to premature nonpropagated His bundle depolarizations: documentation by His bundle electrocardiography. Circulation 1970; 42:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/53\">",
"      Abrams J, Dykstra JR. Pseudo A-V block secondary to concealed junctional extrasystoles. Case report and review of the literature. Am J Med 1977; 63:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/54\">",
"      KURLAND GS, PRESSMAN D. THE INCIDENCE OF ARRHYTHMIAS IN ACUTE MYOCARDIAL INFARCTION STUDIES WITH A CONSTANT MONITORING SYSTEM. Circulation 1965; 31:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/55\">",
"      Scherlag BJ, Lazzara R, Helfant RH. Differentiation of \"A-V junctional rhythms\". Circulation 1973; 48:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/56\">",
"      de CARVALHO A, de ALMEIDA D. Spread of activity through the atrioventricular node. Circ Res 1960; 8:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/57\">",
"      Hariman RJ, Gomes JA, El-Sherif N. Recording of diastolic slope with catheters during junctional rhythm in humans. Circulation 1984; 69:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/58\">",
"      HOFFMAN BF, CRANEFIELD PF. THE PHYSIOLOGICAL BASIS OF CARDIAC ARRHYTHMIAS. Am J Med 1964; 37:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/59\">",
"      Rosen MR, Fisch C, Hoffman BF, et al. Can accelerated atrioventricular junctional escape rhythms be explained by delayed afterdepolarizations? Am J Cardiol 1980; 45:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/60\">",
"      Anderson GJ, Greenspan M, Kimbiris D. Concealed junctional bigeminy inducing pseudo 2:1 AV block. J Electrocardiol 1981; 14:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/441/abstract/61\">",
"      Dhurandhar RW, Valen FJ, Phillips J. Pseudo second degree atrioventricular block with bradycardia. Successful treatment with quinidine. Br Heart J 1976; 38:1363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 932 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_441=[""].join("\n");
var outline_f0_27_441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5230411\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ATRIAL PREMATURE BEATS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence and significance of APBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanisms of APBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Etiology of APBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ECG manifestation and diagnosis of APBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electrophysiology of APBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symptoms associated with APBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination in patients with APBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recommendations for therapy for APBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      JUNCTIONAL PREMATURE BEATS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevalence and significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ECG manifestation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recommendation for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5230411\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/932|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/36/28225\" title=\"figure 1\">",
"      EP study interpolated JPB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/932|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?13/0/13312\" title=\"waveform 1\">",
"      ECG APB noncompensatory pause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/54/39790\" title=\"waveform 2\">",
"      ECG blocked APB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?37/11/38065\" title=\"waveform 3\">",
"      EP study APB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/48/43789\" title=\"waveform 4\">",
"      ECG strip atrial bigeminy and blocked APB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/12/31936\" title=\"waveform 5\">",
"      ECG junctional premature beat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34438?source=related_link\">",
"      ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=related_link\">",
"      Enhanced cardiac automaticity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9320?source=related_link\">",
"      Prevalence and evaluation of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_27_442="Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions";
var content_f0_27_442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/442/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/442/contributors\">",
"     Dennis K Ledford, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/442/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/442/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/27/442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/27/442/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/27/442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is a severe allergic reaction that may cause death. In this topic review, the term anaphylaxis is applied to both IgE-mediated and non IgE-mediated reactions. The evaluation of patients who have experienced perioperative anaphylaxis and strategies for avoiding recurrent reactions during subsequent anesthesia will be reviewed here. The prevalence, etiologies, clinical manifestations, diagnosis, and differential diagnosis of perioperative anaphylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of anaphylaxis is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient who has experienced perioperative or perianesthetic anaphylaxis involves a clinical history, review of records of the event, analysis of laboratory tests obtained at the time, and possibly skin testing if the reaction was suspected to be IgE-mediated.",
"   </p>",
"   <p>",
"    There are two goals of this evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of the culprit agent so that the patient can avoid it in the future. Not identifying the responsible agent necessitates the use of multiple second-line agents, a strategy that is not without risk to the patient",
"     </li>",
"     <li>",
"      Identification of alternative agents to which the patient has no evidence of hypersensitivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103756\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing and challenge procedures to identify drug allergy should be performed by allergy specialists trained in the safe performance and accurate interpretation of these tests and maneuvers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients usually cannot provide much information about reactions that occurred during anesthesia. However, questioning the patient about prior anesthesia may be helpful in identifying previous exposures, as well as agents that were tolerated in the past.",
"   </p>",
"   <p>",
"    An initial step in evaluating a patient with suspected perioperative anaphylaxis is verification that the reaction was clinically consistent with anaphylaxis. Wheezing and urticaria are helpful in distinguishing anaphylaxis from other disorders. The characteristic signs and symptoms of perioperative anaphylaxis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Records of the procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases, the only history available to the evaluating clinician are anesthesia and perioperative records, and perhaps a verbal account from clinicians who were present. A review of drug administration records is essential to determine temporal relationships between the administration of various agents and the onset of symptoms. Operative notes may be helpful for identifying potential exposures to latex (eg, symptoms that began shortly after an internal organ was extensively manipulated and handled).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tests for mast cell mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum or plasma tryptase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histamine elevations measured during or shortly after the reaction should be analyzed. The interpretation of these tests is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If these tests were not obtained at the time of the event but blood samples were drawn for other purposes, it may still be possible to measure serum tryptase (although not histamine), as tryptase is stable in frozen serum for up to one year.",
"   </p>",
"   <p>",
"    In one large series, the estimated positive predictive value of tryptase elevations in 259 subjects with anesthesia-associated anaphylaxis was 93 percent and the estimated negative predictive value of normal tryptase levels was 54 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thus, an elevated tryptase level is highly suggestive of anaphylaxis, although a normal tryptase level does not exclude anaphylaxis.",
"   </p>",
"   <p>",
"    The finding of elevated mast cell mediators indicates that massive mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    degranulation occurred, although it does not provide information about the mechanism (eg, IgE-mediated or other) of the reaction or the culprit trigger.",
"   </p>",
"   <p>",
"    If serum tryptase is elevated, a repeat measurement should be performed when the patient has recovered to assure that levels are not persistently elevated. Patients with persistent elevations above 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    should be evaluated for the rare disorder systemic mastocytosis. If the tryptase is above 11",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    but less than 20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    the individual may be at risk of anaphylaxis due to a monoclonal mast cell disorder or mast cell activation syndrome. The susceptibility of anaphylaxis in this condition has been demonstrated for insect hypersensitivity, although these individuals are likely at increased risk of anaphylaxis from other causes as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=see_link\">",
"     \"Mast cell activation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing (prick-puncture and intradermal) may be considered if the suspect agent is known to cause IgE-mediated reactions (",
"    <a class=\"graphic graphic_table graphicRef60805 \" href=\"UTD.htm?8/5/8284\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Skin testing has no utility in the evaluation of anaphylaxis resulting from other mechanisms. Skin testing is more sensitive than in vitro testing in most cases, although the negative and positive predictive values of skin testing for most drugs is unknown.",
"   </p>",
"   <p>",
"    The groups of agents that have most often been implicated in IgE-mediated perioperative anaphylaxis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neuromuscular blocking agents (NMBAs)",
"     </li>",
"     <li>",
"      Certain antibiotics (particularly beta-lactam antibiotics such as penicillin or cephalosporins)",
"     </li>",
"     <li>",
"      Barbiturate induction agents",
"     </li>",
"     <li>",
"      Latex",
"     </li>",
"     <li>",
"      Vital dyes (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=see_link\">",
"       isosulfan blue",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin testing has also been validated for streptokinase, chymopapain and insulin, although these agents are less often implicated in anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports in the medical literature during the last decade provide evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , an antiseptic commonly used in dental rinses, surgical scrubs, and sterilizing solutions, may cause anaphylaxis. Skin testing with chlorhexidine (0.5 percent chlorhexidine digluconate solution for prick-puncture skin testing, 0.0002 percent for intradermal) is positive in at least some of these cases, suggesting that chlorhexidine may be an important immunologic cause of perioperative anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suggested concentrations for use in skin testing of some agents are provided below. Nonspecific irritant reactions are possible with some drugs, although these should be less likely if the recommended concentrations are not exceeded. Testing with higher concentrations may result in nonspecific positive responses, even in people who have not had adverse reactions to the drug, making the test of no value. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Specific agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We generally test a patient to each of the medications that were administered prior to or during the adverse reaction, placing priority on those agents most likely to cause anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link&amp;anchor=H4#H4\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those agents that have been implicated in causing anaphylaxis through multiple mechanisms (",
"    <a class=\"graphic graphic_table graphicRef60805 \" href=\"UTD.htm?8/5/8284\">",
"     table 1",
"    </a>",
"    ), particularly NMBAs, we also perform skin testing for one or two potential alternative drugs that are used by the anesthesiologist involved in the case. This assists in planning for future episodes of anesthesia. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Neuromuscular blocking agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After an evaluation is performed in which culprit drugs are identified, the patient should be educated about the specific agent that caused the reaction and informed about how best to avoid this and any potentially cross-reacting drugs. The results of the evaluation and advice about avoiding future reactions should be relayed to the patient&rsquo;s primary care provider, anesthesiologist, and surgeon. The patient should consider obtaining a medical identification bracelet or similar device that lists the culprit drug(s).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Timing of skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing is usually delayed for four to six weeks after the reaction, since false negative results are more likely immediately following anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. However, testing may be performed sooner if repeat anesthesia is necessary, as positive tests are still meaningful. Until an evaluation has been completed, the agents statistically more likely to have caused the reaction should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link&amp;anchor=H4#H4\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Accuracy and interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpretation of skin testing requires clinical expertise because the positive and negative predictive values for skin testing with medications have not been systematically defined, with the notable exception of penicillin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these limitations, a positive skin test to an agent that is known to cause IgE-mediated reactions, with appropriate positive (histamine) and negative (saline) controls, is usually interpreted as indicative of allergic sensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Techniques and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy skin testing ideally should only be performed by allergy specialists with training in the proper performance of the technique. Skin testing is considered safe for most patients, although it is not without risk. It is recommended that full emergency equipment and medications, including epinephrine, be present for treatment of the rare, yet potentially life-threatening, anaphylactic event that can arise from the testing. A general review of skin testing techniques is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prick-puncture testing is safer than intradermal testing and is preferred for the initial testing. If prick-puncture testing is negative, intradermal testing can safely proceed. Intradermal testing is more sensitive than prick-puncture testing and thus provides maximal reassurance that the drug in question was not responsible for the adverse event. In general, the maximal concentration used for intradermal testing is 10- to 1000-fold more dilute than that used for prick-puncture testing. However, these concentrations are often determined empirically. The primary concerns are not to use concentrations sufficient to cause an irritant response or anaphylaxis with the testing. Both of these adverse outcomes are more likely with intradermal testing, so a reduction in concentration from that of the prick-puncture testing is employed. The concentration(s) chosen are dependent upon prior experience, perceived risk of anaphylaxis or published case series, and rarely on controlled trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the literature provides a nonirritating concentration for intradermal testing, the same concentration could be used for initial prick-puncture skin testing. After a negative prick-puncture test, then intradermal testing could be performed as this method is more sensitive.",
"     </li>",
"     <li>",
"      If there is no recommended testing concentration available in the literature, we begin prick-puncture testing with a 1:100 to 1:100,000 dilution of the concentration associated with the original reaction. The initial test concentration is based upon the severity of the reaction and the likelihood that the drug in question was responsible. A more dilute concentration may be used for the initial steps of testing if the patient&rsquo;s reaction was particularly severe. Repeat testing is performed with 10-fold increases in concentration until a positive prick-puncture test result or the clinically utilized concentration is reached.",
"      <br/>",
"      <br/>",
"      If all prick-puncture tests were negative, then intradermal testing is performed starting at 1:100 to 1:1000 of the maximum prick-puncture concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/10\">",
"       10",
"      </a>",
"      ]. Serial tests with 10-fold progressive increases in concentration are subsequently performed. The time required for testing may be reduced by utilizing fewer dilutions (eg, 1:100, 1:10, and undiluted) first for prick-puncture testing, followed by the same dilutions for intradermal testing. Some experts are comfortable with this efficiency, while others prefer the additional safety of using more dilute starting solutions.",
"     </li>",
"     <li>",
"      Appropriate positive and negative controls are always required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"       \"Overview of skin testing for allergic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A false positive irritant reaction may occur with both prick-puncture and intradermal testing but is more likely with the latter. If a positive prick-puncture or intradermal test occurs with a medication for which there are no specific, published concentration recommendations, we advise testing several controls (eg, the clinician and a volunteer) to verify that the concentration does not cause a nonspecific, irritant response. The positive and negative predictive values are very limited when performing testing with drugs not rigorously studied, but this is often the only option to provide some guidance with respect to safety if no alternative choices for anesthesia are available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role of in vitro testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro immunoassays for allergen-specific IgE (the modern form of RAST testing using ELISA methodology) may be helpful in identifying the causative agent in IgE-mediated anaphylaxis, although very few of these are available commercially. In addition, some tests that are offered commercially are not validated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    involve drugs which have never been shown to induce IgE antibodies. Thus, skin testing is usually more reliable, in part because skin testing is more sensitive at detecting drug-specific IgE. Neither type of testing has utility in the evaluation of anaphylaxis resulting from mechanisms other than IgE.",
"   </p>",
"   <p>",
"    In vitro testing is mainly utilized in the evaluation of potential reactions to latex. A validated immunoassay to detect latex-specific IgE is commercially available. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Latex'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With the exception of penicillin and several other beta-lactam antibiotics, there are few in vitro tests available for most of the other medications and agents implicated in perioperative anaphylaxis. A detailed discussion of in vitro testing for allergic disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SPECIFIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative anaphylaxis can result from more than one mechanism, and it is important to understand which mechanisms are associated with commonly-implicated agents (",
"    <a class=\"graphic graphic_table graphicRef57346 \" href=\"UTD.htm?1/60/1996\">",
"     table 2",
"    </a>",
"    ). The pathophysiology of these reactions is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link&amp;anchor=H2#H2\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Mechanisms of anaphylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain agents have been repeatedly implicated in perioperative and perianesthesia anaphylaxis, including NMBAs, latex, antibiotics, barbiturate induction agents, blood products, super vital dyes, and possibly analgesics (opioids or nonsteroidal antiinflammatory drugs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neuromuscular blocking agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, 50 to 70 percent of anaphylaxis related to anesthesia is attributed to NMBAs (also referred to as muscle relaxants). Anaphylaxis is less frequently associated with NMBAs in the US. These agents can cause anaphylaxis through both IgE-mediated and direct mast cell activation, although severe, life-threatening reactions are usually IgE-mediated (",
"    <a class=\"graphic graphic_table graphicRef57346 \" href=\"UTD.htm?1/60/1996\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/10\">",
"     10",
"    </a>",
"    ]. The epidemiology and risk factors of hypersensitivity to NMBAs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link&amp;anchor=H6#H6\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Neuromuscular blocking agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The explanation for the difference in prevalence of NMBA-associated anaphylaxis in Europe versus the US may be a result of false positive results when skin testing for NMBA allergy is performed. Some of the NMBAs (those derived from steroids) may induce a wheal and flare skin test response due to direct action on blood vessels. This has been confirmed by almost 50 percent of normal volunteers showing a positive skin response. Since these tests may be used to document NMBAs as a cause of anaphylaxis, the false positive rate with certain agents may result in an exaggeration of the risk, particularly if more concentrated solutions are used for intradermal testing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] . Alternatively, there may be epidemiologic differences between Europe and US that explain the difference.",
"   </p>",
"   <p>",
"    The NMBAs most commonly implicated are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (aka, suxamethonium),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    , mivacurium, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/1/26646?source=see_link\">",
"     cisatracurium",
"    </a>",
"    . Atracurium can cause nonimmunologic release of histamine from mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/11\">",
"     11",
"    </a>",
"    ], and some other drugs with this property (metocurine and tubocurarine) were removed from the US market years ago, but may still be in use in other parts of the world.",
"   </p>",
"   <p>",
"    Cross-reactivity has been documented among NMBAs; thus, patients who react to one NMBA may react to others. This phenomenon has been most often reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine (suxamethonium)",
"    </a>",
"    and gallamine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The shared quaternary ammonium groups in all NMBAs may underlie this phenomenon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link&amp;anchor=H6#H6\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Neuromuscular blocking agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Testing for IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing with NMBAs is not standardized. We begin with prick&ndash;puncture testing, performed as described above and accompanied by a positive and negative control. If there is no reaction to the drug, we then proceed to intradermal testing with concentrations no higher than those listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. Some experts limit the number of tests by using undiluted NMBA for prick-puncture testing and using 1:100 dilution for initial intradermal testing. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Role of skin testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We simultaneously test the patient to one or more alternative drugs, which we obtain from the anesthesiologist involved in the case. This facilitates the selection of an alternative agent for future use, particularly if a positive test occurs.",
"   </p>",
"   <p>",
"    As mentioned previously, this approach may be altered for patients with a very severe past reaction. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Techniques and precautions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The ranges of maximal nonirritating concentrations for INTRADERMAL skin testing in the literature are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       Succinylcholine (suxamethonium)",
"      </a>",
"      : 0.01 to 0.1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"       Rocuronium",
"      </a>",
"      : 0.01 to 0.1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"       Pancuronium",
"      </a>",
"      : 0.02 to 0.2",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"       Vecuronium",
"      </a>",
"      : 0.04 to 0.4",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A range of concentrations is provided because the literature varies as to the maximum, nonirritating concentration. The use of concentrations at the higher end of the range provides the clinician with more confidence that the drug is not the cause of the IgE-mediated reaction, but with increased risk of false positive results. If the test is positive, we usually perform the test on control individuals (the clinician or associates) to be sure the positive is not a nonspecific, irritant reaction.",
"   </p>",
"   <p>",
"    In vitro assays for IgE specific to NMBAs are available in some countries, including the US. Reported assays have up to 88 percent sensitivity but a false positive rate of 5 to 10 percent. If available, these in vitro tests may be of use if skin testing cannot be performed or interpreted, since provocative challenging with NMBAs is not generally feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Evaluation of non IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the skin test to one of these agents were negative and there is concern that a non IgE-mediated reaction may have been responsible, then a challenge protocol is the only definitive means of excluding this possibility. However, there is inherent risk in this approach and, as described in the next section, alternative strategies are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Strategies for future anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with IgE-mediated reactions to NMBAs, we recommend an alternative agent to which the patient has been skin tested and found to be negative.",
"    <span class=\"nowrap\">",
"     Challenge/desensitization",
"    </span>",
"    to an IgE-mediated reaction to NMBA is not feasible so the suspected NMBA must be avoided.",
"   </p>",
"   <p>",
"    If a reaction to a NMBA is suspected clinically but the skin tests are negative, we again recommend an alternative agent to which the patient has been skin tested and found to be negative. If there is no alternative agent with a negative skin test, then the suspect agent could be used again following premedication with antihistamine and possibly glucocorticoid. However, many studies document that no premedication regimen can reliably prevent all, or even most, cases of IgE-dependent anaphylaxis, and the clinician should take all possible precautions to minimize the severity of a reaction (eg lowest possible dose) and must be prepared to treat an adverse event. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'General precautions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Avoidance is always an option if there are other means of providing anesthesia, such as spinal block. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Alternate forms of anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Latex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis to latex is an IgE-mediated process resulting from the formation of specific-IgE against proteins from natural rubber latex. The incidence of latex reactions is much lower than in the 1990s. Compared to reactions to induction agents or NMBAs, latex reactions tend to occur later in procedures (eg, 30 minutes or more after the start of the intervention and often at the time of maximal glove contact with human tissue).",
"   </p>",
"   <p>",
"    The risk factors for developing latex allergy, the sources of latex that are found in the intraoperative setting, and the diagnosis of latex allergy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link&amp;anchor=H7#H7\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Latex'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9785?source=see_link\">",
"     \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Strategies for future anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IgE-mediated latex allergy are usually managed with strict latex avoidance and must undergo all future procedures and surgeries in latex-free environments, which are now available at most hospitals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=see_link\">",
"     \"Latex allergy: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are frequently administered before, during, or immediately after anesthesia. Beta-lactam antibiotics (specifically cephalosporins and penicillins) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    are the most common causes of antibiotic-induced anaphylaxis or reactions that resemble anaphylaxis in the perioperative setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-lactam antibiotics cause IgE-mediated reactions that can be evaluated with appropriate skin testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link\">",
"     \"Penicillin skin testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    reactions are non IgE-mediated reactions and related to the rate of infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Skin testing is usually not performed. However, rare IgE-mediated reactions to vancomycin are reported and should be suspected in patients who have received repeated administrations. If an IgE-mediated reaction is suspected, then skin testing with a maximum intradermal testing concentration of 10",
"    <span class=\"nowrap\">",
"     micrograms/mL",
"    </span>",
"    is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link\">",
"     \"Vancomycin hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Options for retreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IgE-mediated allergies to antibiotics are generally managed by avoidance of the specific culprit drug and closely related drugs. Desensitization can be performed if the culprit antibiotic is required in the future and no acceptable alternative is available. Desensitization is a process by which temporary tolerance to an agent is achieved by administering progressively increasing doses, starting at a dose less than that required to provoke symptoms.",
"   </p>",
"   <p>",
"    Antibiotic desensitization by the oral route is associated with fewer risks than intravenous desensitization and is therefore preferred if an oral preparation is available. However, even an oral challenge may require intensive care observation if the prior reaction was life-threatening.",
"   </p>",
"   <p>",
"    Since many antibiotics do not have an oral formulation, antibiotic desensitizations are often administered intravenously in an intensive care setting, under the supervision of an allergy specialist. The procedure is usually accomplished in a matter of hours. Desensitization protocols for penicillin are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    reactions are rarely IgE-mediated, and the management of patients with non IgE-mediated reactions is based upon the use of antihistamine premedication and slower rates of infusion. Most patients are able to tolerate repeat administration using these techniques. The use of desensitization protocols is an option for patients with recurrent reactions despite slower rates and premedication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link\">",
"     \"Vancomycin hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hypnotic induction agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction agents historically have accounted for up to 5 percent of perioperative anaphylaxis. However, since the removal of cremophor ER&trade; (polyethoxylated castor oil) as a solvent for many of these agents, the incidence of induction agent anaphylaxis has decreased significantly. There are two types of induction agents: barbiturates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    ) and non-barbiturates (eg, benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ). Most reactions are caused by barbiturates and are IgE-mediated, although direct mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation has also been described (",
"    <a class=\"graphic graphic_table graphicRef60805 \" href=\"UTD.htm?8/5/8284\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/4,18-20\">",
"     4,18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link&amp;anchor=H9#H9\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Hypnotic induction agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-barbiturate induction agents can cause direct mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. Specific IgE production to these agents is rare, and skin testing is generally not recommended. Skin testing has been reported for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    but is of unknown value for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/22\">",
"     22",
"    </a>",
"    ]. A case report of very rare anaphylaxis to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    was associated with a positive skin test to the phenol constituent of the preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cross reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is known about cross reactivity between different types of hypnotic induction agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunologic cross reactivity among the barbiturates is possible, and skin testing may be used to select an agent less likely to result in reactions with subsequent procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Barbiturates may cross react with NMBAs due to shared, quaternary amine chemical structures. Caution is recommended with use of NMBAs in subjects with confirmed IgE-mediated reactions to barbiturates. Some experts recommend screening for NMBA sensitivity in subjects with IgE-mediated barbiturate reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is currently no evidence for cross reactivity between the barbiturate and non-barbiturate groups.",
"     </li>",
"     <li>",
"      Cross reactivity between benzodiazepines and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      , the other commonly-used non-barbiturate, has not been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated previously, IgE-mediated reactions to barbiturate agents are well-described. Skin testing for barbiturate induction agents is not standardized. We begin with prick-puncture testing using the diluted or undiluted drug (depending on the severity of the patient's reaction), accompanied by a positive and negative control. If there is no reaction to the drug, we then proceed to serial intradermal testing with concentrations no higher than those listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. When a range of maximal concentrations has appeared in the literature, we utilize the higher concentration:",
"   </p>",
"   <p>",
"    Barbiturate agents:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"       Methohexital",
"      </a>",
"      : 0.1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"       Thiopental",
"      </a>",
"      : 0.2 to 2.5",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-barbiturate agents (skin testing is indicated only rarely if an IgE-mediated reaction is suspected):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       Propofol",
"      </a>",
"      : 1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      : 0.5",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       Etomidate",
"      </a>",
"      : 0.2",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Strategies for future anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with either IgE-mediated or non IgE-mediated reactions to barbiturate agents, we recommend the use of a non-barbiturate agent in future procedures. Desensitization to barbiturates is theoretically possible but not appropriate, because the time required to desensitize the patient would result in prolonged exposure to these agents.",
"   </p>",
"   <p>",
"    If a non IgE-mediated reaction is suspected and there is no suitable alternative agent, then we generally recommend using the suspect agent again and pretreating the patient with antihistamines and possibly glucocorticoids. As mentioned previously, pretreatment regimens may not prevent all recurrent reactions.",
"   </p>",
"   <p>",
"    Avoidance is always an option if there are other means of providing anesthesia, such as spinal block. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Alternate forms of anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narcotics used in anesthesia are common causes of flushing and urticaria following intravenous or intramuscular administration, although these agents rarely cause life-threatening anaphylaxis. Reactions to orally administered narcotics are less common and not as severe.",
"   </p>",
"   <p>",
"    Cutaneous reactions to opioids are almost always non IgE-mediated and occur because of the presence of opioid receptors on dermal mast cells. Binding of the drug to these receptors stimulates release of histamine and other mediators, leading to flushing, urticaria, and angioedema. Opioid receptors have not been demonstrated on mast cells in other organs, which may explain why hypotension and bronchospasm are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions to opioid narcotics are almost always non IgE-mediated, as mentioned above. We do not perform skin testing with narcotics, since nonspecific positive responses are expected due to the nonimmunologic sensitivity of dermal mast cells to these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Strategies to prevent recurrent reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple preparations of opioids are available and repeat exposure to the culprit agent is rarely necessary. We prefer use of a different agent, administered slowly. We have found that premedication is unnecessary for most patients using this approach. However, some patients will have similar reactions to other opioids. In such patients, premedication with antihistamines, with or without glucocorticoids, may help reduce the frequency and severity of recurrent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is unique among narcotics in its lack of mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    stimulating properties, making it a good option for pain management in patients who developed cutaneous reactions with other narcotics [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/19,21,27\">",
"     19,21,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22812258\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with preexisting asthma, especially if there is coexisting hyperplastic sinusitis with or without nasal polyps, are at increased risk of experiencing nonallergic responses that may resemble anaphylaxis, also called pseudoallergic reactions, after administration of NSAIDs. These reactions are characterized by asthma exacerbations with increased upper airway congestion and rhinorrhea. The respiratory response may be very severe and life threatening. Generally these reactions do not occur or have diminished severity with agents that are weak cyclooxygenase I inhibitors, for example",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    , or selective cyclooxygenase II inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/28\">",
"     28",
"    </a>",
"    ]. Urticaria may also occur with certain NSAIDs but this is not usually associated with other features of anaphylaxis such as decrease in blood pressure or respiratory symptoms. Reactions may occur with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    used for antiplatelet effects. Very rarely, IgE sensitivity to NSAID may result in allergic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/28\">",
"     28",
"    </a>",
"    ]. Allergic and pseudoallergic reactions to NSAIDs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22812267\">",
"    <span class=\"h3\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reliable skin or in vitro tests to detect NSAID induced exacerbations of chronic respiratory disease. Graded challenges with NSAIDs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , will detect this sensitivity, but these procedures have risk if not performed under controlled conditions. The best option is to avoid NSAIDs in the perioperative period. Challenge procedures for NSAID pseudoallergic reactions are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=see_link\">",
"     \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22812275\">",
"    <span class=\"h2\">",
"     Blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of blood products, common in the perioperative period, can result in a variety of immunologic reactions, including anaphylaxis. One study observed that 1.3 percent of all transfusion reactions are anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/12\">",
"     12",
"    </a>",
"    ]. Other complex adverse effects may resemble anaphylaxis but be immunologic, nonimmunologic or a mixture of the two. These include fluid overload, hemolytic reactions, and transfusion associated respiratory distress (TRALI) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/12\">",
"     12",
"    </a>",
"    ]. TRALI can mimic anaphylaxis as it results in acute shortness of breath, hypoxemia, and hypotension within one to six hours of a transfusion. TRALI has been reported to be the third most common cause of transfusion-associated death [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/12\">",
"     12",
"    </a>",
"    ]. TRALI is likely the result of antibodies in the transfusate reacting with determinants on blood cells of the recipient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Colloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colloid plasma expanders such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    or hydroxyethyl starch (HES) are solutions of high molecular weight polysaccharides. Anaphylactic reactions to these agents are uncommon, with reported rates of &lt;0.1 percent for each [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/12,18,29,30\">",
"     12,18,29,30",
"    </a>",
"    ]. HES can also cause persistent pruritus that is refractory to therapy and can last for months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/31\">",
"     31",
"    </a>",
"    ]. Dextran is uncommonly used now, although HES is utilized in battle-related trauma.",
"   </p>",
"   <p>",
"    Gelatin in plasma expanders has been implicated in IgE-mediated anaphylactic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Albumin has also been implicated in rare perioperative anaphylactic reactions, although the mechanisms have not been explored [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/13,34\">",
"     13,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with skin testing to colloids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. One case report described testing by prick-puncture method with undiluted preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/18\">",
"     18",
"    </a>",
"    ], although we would suggest additional intradermal testing with 1:100 or 1:10 dilutions. If the results are positive, we would perform the test on control individuals (the clinician or a volunteer) to be sure the positive is not a nonspecific, irritant reaction.",
"   </p>",
"   <p>",
"    An in vitro test for gelatin-specific IgE is commercially available, and skin testing to gelatin has been validated. Skin testing with gelatin is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Radiocontrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with past reactions to radiocontrast agents is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38680?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22812284\">",
"    <span class=\"h2\">",
"     Supravital dyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supravital (ie, capable of staining live cells) or aniline dyes, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=see_link\">",
"     isosulfan blue",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , are used to identify sentinel lymph nodes that are associated with specific anatomic areas with confirmed or suspected malignancy. This technique is used especially with breast cancer. Isosulfan blue has a warning in the package insert of a risk of anaphylaxis of 1 to 3 percent, and sustained and biphasic reactions have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/35\">",
"     35",
"    </a>",
"    ]. The risk of anaphylaxis is probably similar with the chemically-related supravital dye patent blue V and lower with methylene blue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/35-40\">",
"     35-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22812292\">",
"    <span class=\"h3\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prick-puncture and intradermal skin testing may identify the cause of prior anaphylaxis or assess subjects at increased risk for subsequent procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/35,41\">",
"     35,41",
"    </a>",
"    ]. Although additional information is needed to evaluate the positive and negative predictive value of such testing, including the threshold for nonspecific skin irritation, skin testing has been reported with the following concentrations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patent blue V [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/9,41\">",
"       9,41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      1:10 dilution, increasing if negative to undiluted (25",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      for prick puncture",
"     </li>",
"     <li>",
"      1:100 dilution or a 1:10 dilution (2.5",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      for intradermal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       Methylene blue",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/9\">",
"       9",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Undiluted (10",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      for prick puncture",
"     </li>",
"     <li>",
"      1:100 dilution (0.1",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      for intradermal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=see_link\">",
"       Isosulfan blue",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Undiluted (1 percent stock) for prick puncture",
"     </li>",
"     <li>",
"      1:100 dilution for intradermal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22812300\">",
"    <span class=\"h3\">",
"     Strategies for future anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects with past history of reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=see_link\">",
"     isosulfan blue",
"    </a>",
"    could be assessed for sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    or vice versa, but the predictive value of allergy skin testing is not established. Methylene blue is less likely to result in hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/38\">",
"     38",
"    </a>",
"    ]. Radioactive colloid may be used as an alternative to sentinel node detection but the inability of the surgeon to visually confirm the node limits this approach. Antihistamine and glucocorticoid pretreatment is not supported by specific evidence but with mild or atypical reactions this approach may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     APPROACH TO FUTURE ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safest approach for managing future anesthesia in a patient who suffered perioperative anaphylaxis is avoidance of the culprit agent. Therefore, every effort should be made to identify the responsible trigger, so that the patient is not restricted to receiving multiple second-line agents. Unfortunately, even a very thorough evaluation may reveal no evidence of allergy to one specific agent. In these cases, future management involves avoidance of high risk agents and adherence to the general precautions discussed below. In addition, alternate forms of anesthesia may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     General precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;For any patient with a history of perioperative anaphylaxis, there are several general precautions which should be applied to future procedures requiring anesthesia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with asthma should have respiratory symptoms as well controlled as possible prior to receiving anesthesia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"       \"Evaluation of preoperative pulmonary risk\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta-blockers should be avoided, if possible, especially if the culprit agent could not be conclusively identified. Beta-blockers may increase the severity of anaphylaxis and reduce responsiveness to epinephrine. However, some patients may have cardiovascular conditions for which beta-blockade is critical, and these cases require multidisciplinary consideration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H15#H15\">",
"       \"Anaphylaxis: Rapid recognition and treatment\", section on 'Concurrent medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ACE inhibitors may interfere with compensatory physiologic responses to anaphylaxis and exaggerate bradykinin-induced vascular changes, although these data are not robust. The decision to discontinue these medications prior to repeat anesthesia depends upon the severity of the reaction, and on whether a specific cause could be implicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H15#H15\">",
"       \"Anaphylaxis: Rapid recognition and treatment\", section on 'Concurrent medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drugs that can cause direct release of histamine from mast cells and basophils (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , quaternary NMBAs) should be administered as slowly as possible, particularly if they are being infused in close temporal proximity (",
"      <a class=\"graphic graphic_table graphicRef60805 \" href=\"UTD.htm?8/5/8284\">",
"       table 1",
"      </a>",
"      ). Drugs that do not have these properties, if available, should be given instead.",
"     </li>",
"     <li>",
"      Intraoperative antibiotics should be administered slowly, with careful hemodynamic monitoring. Loading or initial doses should be given prior to induction of anesthesia, while the patient is awake, whenever possible.",
"     </li>",
"     <li>",
"      Verification that baseline total serum tryptase is not elevated may be helpful to identify subjects at increased risk of anaphylaxis due to clonal mast cell disorders (&gt;11",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      or mastocytosis (&gt;20",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"      Additional precautions should be implemented in such individuals as they are at increased risk of anaphylaxis in general. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment and prognosis of systemic mastocytosis\", section on 'Preparation for medical and surgical procedures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Alternate forms of anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other forms of anesthesia, such as local or spinal anesthesia, should be considered, particularly if the reaction was notably severe or the cause could not be identified.",
"   </p>",
"   <p>",
"    Perioperative anaphylaxis has been reported in patients receiving epidural anesthesia, although the rate of recurrent reactions in patients who initially reacted during general anesthesia and later received spinal anesthesia is unstudied [",
"    <a class=\"abstract\" href=\"UTD.htm?0/27/442/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. It is our experience that spinal or epidural anesthesia is generally successful. If the patient has a history of reacting to local anesthetic agents, then skin testing can be performed in advance to the drug that will be used, to ensure that there is no evidence of IgE-mediated allergy to that drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evaluation of perioperative anaphylaxis involves a clinical history, review of records of the event, and review of any tests for mast cell mediators that were obtained at the time. If an IgE-mediated reaction is suspected or likely, skin testing or in vitro testing for allergen-specific IgE should be considered. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgE-mediated reactions are most common with NMBAs (muscle relaxants), latex, antibiotics (particularly penicillins and cephalosporins),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=see_link\">",
"       isosulfan blue",
"      </a>",
"      , and barbiturate induction agents. Skin tests can be performed for each of these agents, although commercial preparations for latex are not currently available in the United States. Skin testing should be performed by allergy specialists. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Role of skin testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In vitro tests for allergen-specific IgE are available for latex and a very limited number of other agents (eg, penicillin and NMBAs in some countries). In vitro testing is generally less sensitive than skin testing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Role of in vitro testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perioperative anaphylaxis can result from more than one mechanism, and it is important to understand which mechanisms are associated with each specific agent, as well as what type of testing is relevant (",
"      <a class=\"graphic graphic_table graphicRef60805 \" href=\"UTD.htm?8/5/8284\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Specific agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The safest management approach for a patient with past anaphylaxis is the definitive identification and complete avoidance of the trigger. If this is not possible or evaluation does not reveal a specific culprit, then future management is based upon avoidance of high risk agents and implementation of general precautions. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Approach to future anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require repeat anesthesia, general precautionary measures include optimal preoperative control of asthma, slow administration of antibiotics and other high risk agents, and avoidance (when possible) of beta-blockers, ACE inhibitors, and drugs that cause direct histamine release from mast",
"      <span class=\"nowrap\">",
"       cells/basophils.",
"      </span>",
"      Spinal or epidural anesthesia is also an option. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Approach to future anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/1\">",
"      Mertes PM, Tajima K, Regnier-Kimmoun MA, et al. Perioperative anaphylaxis. Med Clin North Am 2010; 94:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/2\">",
"      Mertes PM, Laxenaire MC, Alla F, Groupe d'Etudes des R&eacute;actions Anaphylacto&iuml;des Peranesth&eacute;siques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003; 99:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/3\">",
"      Chacko T, Ledford D. Peri-anesthetic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/4\">",
"      Moscicki RA, Sockin SM, Corsello BF, et al. Anaphylaxis during induction of general anesthesia: subsequent evaluation and management. J Allergy Clin Immunol 1990; 86:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/5\">",
"      Beaudouin E, Kanny G, Morisset M, et al. Immediate hypersensitivity to chlorhexidine: literature review. Eur Ann Allergy Clin Immunol 2004; 36:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/6\">",
"      Garvey LH, Kr&oslash;igaard M, Poulsen LK, et al. IgE-mediated allergy to chlorhexidine. J Allergy Clin Immunol 2007; 120:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/7\">",
"      Culp JA, Palis RI, Castells MC, et al. Perioperative anaphylaxis in a 44-year-old man. Allergy Asthma Proc 2007; 28:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/8\">",
"      Hepner DL, Castells MC. Anaphylaxis during the perioperative period. Anesth Analg 2003; 97:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/9\">",
"      Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol 2011; 21:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/10\">",
"      Baldo BA, Fisher MM. Mechanisms in IgE-dependent anaphylaxis to anesthetic drugs. Ann Fr Anesth Reanim 1993; 12:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/11\">",
"      Veien M, Szlam F, Holden JT, et al. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000; 92:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/12\">",
"      Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 2008; 106:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/13\">",
"      Leynadier F, Sansarricq M, Didier JM, Dry J. Prick tests in the diagnosis of anaphylaxis to general anaesthetics. Br J Anaesth 1987; 59:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/14\">",
"      Baldo BA, Fisher MM. Anaphylaxis to muscle relaxant drugs: cross-reactivity and molecular basis of binding of IgE antibodies detected by radioimmunoassay. Mol Immunol 1983; 20:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/15\">",
"      Rose M, Fisher M. Rocuronium: high risk for anaphylaxis? Br J Anaesth 2001; 86:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/16\">",
"      Renz CL, Laroche D, Thurn JD, et al. Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions. Anesthesiology 1998; 89:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/17\">",
"      Anne' S, Middleton E Jr, Reisman RE. Vancomycin anaphylaxis and successful desensitization. Ann Allergy 1994; 73:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/18\">",
"      Birnbaum J, Porri F, Pradal M, et al. Allergy during anaesthesia. Clin Exp Allergy 1994; 24:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/19\">",
"      Genovese A, Stellato C, Marsella CV, et al. Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Int Arch Allergy Immunol 1996; 110:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/20\">",
"      Hirshman CA, Edelstein RA, Ebertz JM, Hanifin JM. Thiobarbiturate-induced histamine release in human skin mast cells. Anesthesiology 1985; 63:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/21\">",
"      Pepys J, Pepys EO, Baldo BA, Whitwam JG. Anaphylactic/anaphylactoid reactions to anaesthetic and associated agents. Skin prick tests in aetiological diagnosis. Anaesthesia 1994; 49:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/22\">",
"      Mertes PM, Laxenaire MC, Lienhart A, et al. Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J Investig Allergol Clin Immunol 2005; 15:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/23\">",
"      de Leon-Casasola OA, Weiss A, Lema MJ. Anaphylaxis due to propofol. Anesthesiology 1992; 77:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/24\">",
"      Fahmy NR. Hemodynamics, plasma histamine, and catecholamine concentrations during an anaphylactoid reaction to morphine. Anesthesiology 1981; 55:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/25\">",
"      Ledford DK. Allergy, anaphylaxis and general anesthesia. Immunology Allergy Clin North Am 2001; 21:795.",
"     </a>",
"    </li>",
"    <li>",
"     Lieberman P. Anaphylaxis and anaphylactoid reactions. In: Middleton's allergy: Principles and practice, 6th ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis 2003. p.1497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/27\">",
"      Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985; 62:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/28\">",
"      Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/29\">",
"      Zinderman CE, Landow L, Wise RP. Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J Vasc Surg 2006; 43:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/30\">",
"      Wiedermann CJ. Hydroxyethyl starch--can the safety problems be ignored? Wien Klin Wochenschr 2004; 116:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/31\">",
"      Bork K. Pruritus precipitated by hydroxyethyl starch: a review. Br J Dermatol 2005; 152:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/32\">",
"      Vervloet D, Senft M, Dugue P, et al. Anaphylactic reactions to modified fluid gelatins. J Allergy Clin Immunol 1983; 71:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/33\">",
"      Russell WJ, Fenwick DG. Anaphylaxis to Haemaccel and cross reactivity to Gelofusin. Anaesth Intensive Care 2002; 30:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/34\">",
"      Fujita A, Kitayama M, Hirota K. Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting. J Anesth 2007; 21:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/35\">",
"      Mertes PM, Malinovsky JM, Mouton-Faivre C, et al. Anaphylaxis to dyes during the perioperative period: reports of 14 clinical cases. J Allergy Clin Immunol 2008; 122:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/36\">",
"      Scherer K, Studer W, Figueiredo V, Bircher AJ. Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes. Ann Allergy Asthma Immunol 2006; 96:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/37\">",
"      Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002; 95:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/38\">",
"      Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg 2005; 189:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/39\">",
"      Dewachter P, Castro S, Nicaise-Roland P, et al. Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 2011; 106:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/40\">",
"      Dewachter P, Mouton-Faivre C, Tr&eacute;chot P, et al. Severe anaphylactic shock with methylene blue instillation. Anesth Analg 2005; 101:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/41\">",
"      Haque RA, Wagner A, Whisken JA, et al. Anaphylaxis to patent blue V: a case series and proposed diagnostic protocol. Allergy 2010; 65:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/42\">",
"      Fisher M. Anaphylaxis to anaesthetic drugs. Novartis Found Symp 2004; 257:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/27/442/abstract/43\">",
"      Ljungstr&ouml;m KG, Renck H, Strandberg K, et al. Adverse reactions to dextran in Sweden 1970-1979. Acta Chir Scand 1983; 149:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2081 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_442=[""].join("\n");
var outline_f0_27_442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103756\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Records of the procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tests for mast cell mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Timing of skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Accuracy and interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Techniques and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role of in vitro testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SPECIFIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neuromuscular blocking agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Testing for IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Evaluation of non IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Strategies for future anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Latex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Strategies for future anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Options for retreatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hypnotic induction agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cross reactivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Strategies for future anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Opioids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Strategies to prevent recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22812258\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22812267\">",
"      - Testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22812275\">",
"      Blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Colloids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Radiocontrast agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22812284\">",
"      Supravital dyes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22812292\">",
"      - Testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22812300\">",
"      - Strategies for future anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      APPROACH TO FUTURE ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      General precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Alternate forms of anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2081\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2081|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/5/8284\" title=\"table 1\">",
"      Periop ana agents mech",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/60/1996\" title=\"table 2\">",
"      Imm and nonimm anaphylx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=related_link\">",
"      Diagnostic challenge and desensitization protocols for NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38680?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=related_link\">",
"      Mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=related_link\">",
"      Penicillin skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_27_443="Risk of cervical CA with HPV";
var content_f0_27_443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of cervical cancer with human papillomavirus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       High-risk (oncogenic or cancer-associated) types",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Common types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 82",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Low-risk (non-oncogenic) types",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Common types: 6, 11, 40, 42, 43, 44, 54, 61, 72, 81",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Centers for Disease Control and Prevention. National Cancer Institute Factsheet. Human papillomavirus and cancer: Questions and answers. Available at: www.cancer.gov/cancertopics/factsheet/Risk/HPV (Accessed on June 11, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_443=[""].join("\n");
var outline_f0_27_443=null;
var title_f0_27_444="Evaluation of HH";
var content_f0_27_444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested evaluation of signs and symptoms in patients with hemochromatosis and iron overload",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indicated evaluations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weakness, fatigue, malaise",
"       </td>",
"       <td>",
"        Evaluation for liver, endocrinologic, and cardiac disorders and for anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated hepatic enzyme&nbsp;concentrations",
"       </td>",
"       <td>",
"        Evaluation for hepatitis B, hepatitis C, and other liver",
"diseases (such as drug-related hepatopathy, alpha-1-antitrypsin",
"deficiency, or metastatic cancer); liver biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly or hepatic&nbsp;pain",
"       </td>",
"       <td>",
"        Evaluation for hepatitis B, hepatitis C,&nbsp;and other liver diseases; liver biopsy;&nbsp;measurement of alpha-fetoprotein&nbsp;concentration; hepatic imaging&nbsp;procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthralgias or arthropathy",
"       </td>",
"       <td>",
"        Radiography of affected joints; evaluation for other arthropathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid dysfunction",
"       </td>",
"       <td>",
"        Measurement of thyroid-stimulating hormone, thyroxine, and antithyroid antibody concentration if hypothyroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impotence, premature&nbsp;amenorrhea",
"       </td>",
"       <td>",
"        Measurement of luteinizing hormone follicle-stimulating",
"hormone, and sex hormone concentrations; computed tomography of",
"anterior pituitary to evaluate for possible pituitary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac symptoms",
"       </td>",
"       <td>",
"        Electrocardiography; echocardiographic assessment of ventricular ejection fraction and exercise tolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperglycemia or diabetes mellitus",
"       </td>",
"       <td>",
"        Fasting serum glucose and glycosylated hemoglobin levels",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Barton, JC, McDonnell, SM, Adams, PC, Ann Intern Med 1998; 129:932.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_444=[""].join("\n");
var outline_f0_27_444=null;
var title_f0_27_445="Differential diagnosis of prolonged crying";
var content_f0_27_445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of identifiable causes of prolonged crying in an infant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            General",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug ingestion or overdosage (eg, pseudoephedrine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Open diaper pin in the skin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hair tourniquet of digit or penis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Eyes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Foreign body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glaucoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corneal abrasion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Ears, nose, oropharynx",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Otitis media",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nasal congestion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thrush",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiovascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Supraventricular tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anomalous origin of left coronary artery",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intussusception",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Constipation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anal fissures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inguinal hernia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroesophageal reflux",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Volvulus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genitourinary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meatal ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Torsion of testis or ovary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skeletal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fracture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteomyelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Abusive head injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_445=[""].join("\n");
var outline_f0_27_445=null;
var title_f0_27_446="Menstrual interval";
var content_f0_27_446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Age-related interval between menses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 247px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Selected percentiles for the distribution of menstrual interval by age based on data from over 200,000 cycles. Longer intermenstrual intervals occur in women just after menarche and in the years preceding menopause.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Treloar, AE, Boynton, RE, Behn, BG, Brown, BW, Int J Fertil 1967; 12:77.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_446=[""].join("\n");
var outline_f0_27_446=null;
var title_f0_27_447="Intravenous pyelogram in medullary sponge kidney";
var content_f0_27_447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravenous pyelogram in medullary sponge kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravenous pyelogram with tomography in medullary sponge kidney. All of the calyces are abnormal (seen best in the left kidney), showing a brushlike appearance radiating outward from the calyces (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Rose, BD, Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_27_447=[""].join("\n");
var outline_f0_27_447=null;
